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CHAPTER I 
 
INTRODUCTION 
 
Stroke  
Stroke is the most serious and debilitating neurological disorder in the United 
States.  It is the third leading cause of death in this country after cancer and heart disease 
(Lloyd-Jones et al., 2009).  Moreover, stroke is the leading cause of severe, long-term 
adult disability, accounting for $68.9 billion in health care costs and economic losses in 
the US in 2009 alone (Lloyd-Jones et al., 2009).  The most recent statistical update by the 
American Heart Association Statistics Committee and Stroke Statistics Subcommittee 
underscores these somber statistics citing that approximately 795,000 people in the US 
experience a new or recurrent stroke, of which 610,000 cases are first attacks (Lloyd-
Jones et al., 2009).   
 
Stroke subtypes  
Strokes are predominately ischemic in nature, comprising 87% of all strokes 
(Lloyd-Jones et al., 2009) (FIGURE 1.1).  An ischemic stroke is defined as the presence 
of a thrombosis, stenosis, embolism or systemic-hypoperfusion leading to the obstruction 
of blood flow to the brain, thereby decreasing the amounts of oxygen and glucose 
reaching this organ (Doyle et al., 2008).  Of all patients suffering from ischemic stroke, 
70% present with a cerebral artery occlusion (Kidwell et al., 2004).  The remaining 13% 
of all strokes are hemorrhagic in nature (FIGURE 1.1), resulting from the rupture of a 
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blood vessel in the brain and subsequently leading to the leakage of blood into the 
surrounding brain tissue (Winkler et al., 2001).  
  
 
 
 
 
 
 
While the numbers of strokes are massive, these do not take into account the 
incidence of silent strokes.  Silent strokes are defined as lesions that are comparable to 
cerebral infarcts and hemorrhages from a neuroimaging and neuropathological 
perspective, yet they do not show the characteristic clinical symptoms associated with 
symptomatic stroke (Leary et al., 2003).  Despite the lack of clinical symptoms, silent 
strokes are associated with substantial neurological, medical and psychiatric deficits 
(Leary et al., 2003).  It is suggested that the number of silent stroke incidences increases 
with age, and statistical analyses from 1998 revealed that in the United States, 9,040,000 
cases of silent strokes were ischemic in nature, while 1,940,000 cases were hemorrhagic 
in nature (Leary et al., 2003).  Furthermore, to accurately assess annual stroke incidences, 
one would also have to include patients experiencing transient ischemic attacks (TIAs) 
83%
17%
Ischemic Strokes 
Hemorrhagic Strokes 
FIGURE 1.1:  Statistical analysis of stroke subtypes.  Out of all strokes, 83% are 
ischemic in nature, indicating that the presence of an embolism, plaque, stenosis or 
hypoperfusion results in the obstruction of blood flow to the brain.  The remaining 17% 
are hemorrhagic in nature, resulting from the rupture of a blood vessel in the brain and 
subsequently leading to the leakage of blood into the surrounding brain tissue.  
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(Leary et al., 2003), which are defined as “a sudden, focal neurological deficit that lasts 
for less that 24 hours” (Albers et al., 2002).  Unlike symptomatic strokes, TIAs do not 
result in permanent brain damage (Albers et al., 2002).   Taken together, these numbers 
and facts not only underscore that the actual annual stroke burden is highly 
underestimated, but also point to a pressing need to even better understand the biology 
underlying stroke.  Improved identification of candidates that are at high risk for either 
symptomatic or asymptomatic stroke would enable more accurate and efficient treatment 
with appropriate therapeutics at the earliest possible time point, with the ultimate goal of 
preventing the occurrence of an actual stroke.  
 
Stroke treatment – Lost in translation? 
Research aimed at identifying and understanding molecular pathways involved in 
neuronal death following ischemic stroke has advanced at an impressive rate uncovering 
a myriad of complex cellular processes that trigger cell death.  Processes leading to 
neuronal death following ischemic stroke include ionic imbalance, peri-infarct 
depolarization, glutamate mediated excitotoxicity, oxidative stress and apoptosis (Doyle 
et al., 2008, Mehta et al., 2007, Onteniente et al., 2003) (FIGURE 1.2).  Notably, the 
same fundamental processes cut across the boundaries of other neurological diseases 
including Parkinson’s, Alzheimer’s and Huntington’s diseases (Choi, 1992, Greene et al., 
1996). 
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Despite our wealth of knowledge regarding the pathology of delayed neuronal 
death following ischemic stroke, clinical trials aimed at blocking these events have been 
extremely disappointing.  We have failed to develop any safe and effective 
neurotherapeutics that can prevent stroke-induced cell death.  Of the more than 100 
agents that were assessed in Phase I-III clinical trials, only one pharmacological agent has 
been approved by the Food and Drug Administration for use in acute ischemic stroke: the 
thrombolytic tissue-plasminogen activator (t-PA) (Johnston, 2006).  t-PA dissolves blood 
FIGURE 1.2:  Approximate timeline of molecular pathway onsets following ischemic 
stroke.  Obstruction of blood flow to the brain via the presence of a thrombosis, embolism 
or systemic-hypoperfusion results in a drastic reduction in ATP production with 
ultimately leads to the initiation of the depicted ischemic cascade which ultimately results 
in neuronal death.  
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clots and re-establishes blood flow to the tissue downstream of the occluded cerebral 
artery (Armstead et al., 2006, Johnston, 2006).  When administered intravenously within 
the first three hours of stroke onset, t-PA can dramatically improve clinical outcome 
(Liberatore et al., 2003, Lopez-Atalaya et al., 2008).  This tight time window has recently 
been expanded to 4.5 hours (Gupta et al., 2006, Lansberg & Schrooten et al., 2009).  In 
spite of the promise of t-PA, less than 3% of eligible patients receive thrombolytic 
therapy.  This huge clinical gap has been attributed to the lack in awareness and 
education regarding t-PA as well as the failure of patients to arrive at hospitals within the 
therapeutic time window (Armstead et al., 2006).  While there are clear benefits of t-PA, 
studies have, however, shown that prolonged or delayed use of t-PA is not without risk.  
Due to its function as a serine protease, t-PA can cross the blood-brain barrier, destroy 
the brain parenchyma and thereby contribute to the increased risk of intracranial 
hemorrhage that is observed in these stroke patients (Armstead et al., 2006, Lansberg & 
Bluhmki et al., 2009, Lansberg & Schrooten et al., 2009, Liberatore et al., 2003, Marler, 
1995).   
While the goal of t-PA therapy is to re-establish circulation to an ischemic area, a 
multitude of studies has been conducted with the goal to identify bona fide 
neuroprotective agents which block neurodegeneration in the hours to days following 
stroke.  The National Institute of Neurological Disorders and Stroke (NINDS) invested 
more than $200 million on stroke clinical trials from 1977-2002 (Marler, 2002).  While 
many of these drugs were successful in preclinical stroke models, not a single therapy has 
proven to decrease morbidity and mortality in the clinical setting (Doyle et al., 2008).  
This issue has been extensively reviewed in an attempt to identify potential areas that 
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may have contributed to the startling failure to translate successful results obtained in 
basic science laboratories into the clinical setting.  Amongst these, the appropriateness of 
experimental animals as well as commonly used in vitro stroke models has been 
criticized (O'Collins et al., 2006).  With regard to experimental animals, there is a lack of 
model systems aside from rodents, and within rodent systems themselves, there is a 
deficiency in data from aging and diseased animals (O'Collins et al., 2006, Savitz et al., 
2007).  Moreover, data evaluating long-term neurological outcomes, complex behaviors 
and lasting benefits of treatments are also absent from current preclinical studies (Savitz 
et al., 2007).  In the context of in vitro model systems of stroke, many preclinical trials 
focus on the role of a single molecular pathway governing cell fate, whereas a plethora of 
events are elicited in this heterogeneous disease (FIGURE 1.2) (O'Collins et al., 2006).  
More to the point perhaps, is the average lag of 7 years between the initial scientific 
findings obtained from in vivo and in vitro models and the actual onset of clinical trials, 
thereby further complicating the transition from bench to bedside (Johnston, 2006). 
 
Stroke pathology and molecular events elicited following ischemic stroke 
Despite the apparent failure to translate basic science results into the clinical 
setting, the few drugs available for use against stroke-induced cell death emerged from 
the knowledge gained from basic science research using in vivo and in vitro model 
systems of stroke.  It is due to these results that scientists and clinicians were able to 
formulate and develop effective approaches aimed not only at preventing disease, but 
also at treating a multitude of human diseases (Lenfant, 2003).  As a result, basic science 
research needs to advance further in the quest to either identify novel, safe and effective 
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therapeutics for the use in ischemic stroke, or to improve the current understanding of 
previously identified agents in order to determine why certain agents failed in the clinical 
setting.  To underline potential sites for neurotherapeutic intervention, major molecular 
events elicited following stroke will be chronologically examined in this chapter.      
 
Changes in energy metabolism following ischemic stroke  
Under normoxic conditions, neurons conduct electrical impulses in the form of 
action potentials, a process dependent upon Na+, K+ and Ca2+ homeostasis.  Fully 50-60% 
of the total ATP synthesized in the brain is used for the maintenance of these 
electrochemical concentration gradients (Erecinska et al., 1994).  During ischemic stroke, 
obstruction of cerebral blood flow (CBF) to the brain and the subsequent lack of oxygen 
and glucose supply results in a drastic reduction in aerobic ATP production.  Using in 
vivo rat models of transient ischemia, studies have demonstrated that total ATP levels 
drop precipitously within 2 minutes following the insult (Doyle et al., 2008, Erecinska et 
al., 1994, Lipton, 1999, Onteniente et al., 2003).  Moreover, glucose levels drop to 50% 
of baseline values and ATP levels drop to approximately 25% of normal values in the 
ischemic core, which is the brain region of maximum and irreversible damage (Lipton, 
1999).  The use of in vivo rat model systems of ischemic stroke have furthermore 
demonstrated  that ATP levels in the core remain decreased between 5min and 4hr after 
the ischemic insult and return to approximately two-thirds of basal values upon 
reperfusion (Lipton, 1999).   
In contrast, within the penumbra, the brain region surrounding the core where 
neurons are functionally impaired yet potentially salvageable, glucose utilization initially 
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increases at early time points, but falls to about 50% of normal values by 3.5hr.  Notably, 
ATP levels in the ischemic penumbra rapidly drop to about 50-70% of basal levels 
(Lipton, 1999) resulting in the inability of neurons to maintain their ionic homeostasis 
(Doyle et al., 2008).  The subsequent intracellular increase in Na+ and decrease in K+ 
leads to the depolarization of neuronal membranes (Onteniente et al., 2003).  In the 
ischemic core, this sudden and profound loss of membrane potential is termed anoxic 
depolarization, an event which is characterized by neuronal death following the opening 
of voltage gated Ca2+ channels and rapid influx of Ca2+ into neurons (Jarvis et al., 2001, 
Joshi et al., 2001, Mehta et al., 2007, Onteniente et al., 2003).  The core propagates 
spontaneous electrical waves known as peri-infarct depolarizations (PIDs) to the 
penumbra, leading to a rapid cycling of de- and repolarizations within these neurons 
(Fabricius et al., 2006, Mehta et al., 2007, Onteniente et al., 2003).  While anoxic 
depolarizations occur within minutes following the initial insult, recurring PIDs occur in 
the penumbra 3-4hr following stroke, setting the stage for further degeneration (Joshi et 
al., 2001, Onteniente et al., 2003).   
 
Glutamate release and excitotoxicity 
The initial loss of ATP and the resulting inability of molecular pumps to maintain 
ionic gradients across the neuronal membrane ultimately results in the depolarization of 
neurons, an event which is accompanied by the influx of Ca2+ into neurons via voltage 
gated Ca2+ channels (Mehta et al., 2007).  Ca2+ triggers the release of neurotransmitters, 
notably glutamate, which is the major excitotoxic neurotransmitter in the CNS (Kandel et 
al., 1999).  The use of in vivo brain microdialysis studies has shown that under 
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physiological conditions, cytosolic glutamate concentrations reach up to 10mM, while 
synaptic glutamate concentrations range between 1-5μM (Doyle et al., 2008, Lipton, 
1999, Matsumoto et al., 1996, Mehta et al., 2007).  Following ischemic stroke, glutamate 
levels can reach concentrations that are up to 100 times higher than under basal 
conditions (Kanthan et al., 1995).  Moreover, regions rich in glutamatergic innervation 
such as the cortex and hippocampus are some of the most vulnerable to ischemic stroke 
(Benveniste et al., 1984).  
The presence of sodium-dependent glutamate transporters in pre- and 
postsynaptic membranes is directly involved in the regulation of cellular signaling by 
assuring the maintenance of appropriate glutamate gradients across the plasma membrane 
as well as proper clearing of glutamate from the synaptic cleft (Doyle et al., 2008).  The 
rise in cytosolic Na+ concentrations following ischemic stroke results in the reversal of 
glutamate transporters, allowing glutamate to flow from the cytosol into the synaptic cleft 
down its concentration gradient (Doyle et al., 2008).  The reversal of the activity of the 
glutamate transporters prevents the reuptake of glutamate into the cell, thus allowing 
extracellular glutamate concentrations to reach neurotoxic levels (Doyle et al., 2008).  
Using microdialysis in animal models of transient ischemia, Benveniste and colleagues 
demonstrated that extracellular glutamate concentrations in the hippocampus start to rise 
within the first 1-2min following the insult and can reach concentrations ranging between 
16 and 30μM within 15min upon transient ischemia (Benveniste et al., 1984).  The 
presence of high levels of glutamate within the synaptic cleft results in massive 
overactivation of ionotropic glutamate receptors, including the N-methyl-D-aspartate 
(NMDA) and the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
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receptors.  The pathological overstimulation of these receptors in combination with 
downstream activation of cell death signaling pathways is commonly referred to as 
“excitotoxicity” (Brouns et al., 2009, Choi, 1992, Greene et al., 1996, Martin et al., 
1998).  NMDA receptors are the prominent route of Ca2+ influx during glutamatergic 
transmission.  Opening of these ligand gated channels results in potentially neurotoxic 
increases in intracellular Ca2+ levels (Mehta et al., 2007).  While Ca2+ is involved in the 
regulation of a variety of adaptive cellular processes including cell growth, differentiation 
and enzyme function, high intracellular Ca2+ levels can promote the activation of cellular 
cascades leading to cell death (Mehta et al., 2007, Onteniente et al., 2003).   
In contrast to NMDA receptors, AMPA receptors are impermeable to Ca2+ by 
virtue of their GluR2 subunit.  Interestingly, studies using the oxygen glucose deprivation 
(OGD) paradigm as an in vitro model to investigate brain ischemia demonstrated that 
both mRNA and protein levels of the GluR2 subunit are substantially reduced following 
ischemia and that the insertion of GluR2-lacking AMPA receptors into the postsynaptic 
membrane is promoted, thereby further increasing Ca2+ influx (Gorter et al., 1997, Liu et 
al., 2006, Noh et al., 2005, Pellegrini-Giampietro et al., 1992).   
The sustained increase in intracellular Ca2+ levels results in the initiation of a 
plethora of cytosolic and nuclear events.  These include generation of reactive oxygen 
species (ROS) and activation of Ca2+-dependent enzymes, such as calpains, 
endonucleases, phospholipase A, cyclooxygenases and neuronal nitric oxide synthase 
(nNOS) which govern extensive cellular damage (Goll et al., 2003, Lipton, 1999, Mehta 
et al., 2007).  For instance, the activation of both the micromolar-Ca2+ requiring calpain  
(μ-calpain) and the millimolar-Ca2+ requiring calpain (m-calpains) has been associated 
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with the pathology of ischemic stroke (Goll et al., 2003), as these proteases are involved 
in activating apoptosis via their ability to cleave and activate caspase-9 (Goll et al., 
2003).  Moreover, calpains have also been shown to increase mitochondrial permeability 
transition activities, thereby leading to mitochondrial damage and the initiation of 
programmed cell death (Arrington et al., 2006, Lipton, 1999, Polster et al., 2005).  Other 
targets of calpains include cytoskeletal proteins, such as MAP2, tubulin and spectrin, 
leading to the disruption of cytoskeletal networks and resulting in cell death (Lipton, 
1999).  In addition to apoptosis, morphological changes characteristic of necrotic and 
autophagic cell death have been noted to be involved in neuronal death following 
ischemic stroke (Adhami et al., 2006, Chu, 2008, Garcia et al., 1995, Martin et al., 1998, 
Sairanen et al., 2006, Unal-Cevik et al., 2004).   
 
Oxidative Stress 
Oxygen (O2) is an essential element for the survival of all aerobic species.  It is 
involved in a variety of processes including respiration and production of energy in the 
form of ATP by means of the mitochondrial electron transport chain.  While the 
importance of oxygen for survival is indisputable, the risks harbored by this element and 
the fact that aerobic species are solely able to survive in the presence of oxygen due to 
the evolution of antioxidant systems are often times disguised.  The dangers and 
damaging effects of oxygen lie in the generation of oxygen radicals, a process which 
predominantly occurs during oxidative energy metabolism in the mitochondria (Halliwell 
et al., 2007, Kleinhans et al., 2006).   
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By definition, a free radical is any molecule that contains an unpaired electron in 
its outermost orbital and is therefore capable of oxidizing other molecules (Gilgun-Sherki 
et al., 2002, Halliwell et al., 2007, Lambert et al., 2009).  In its ground state, O2 has two 
unpaired electrons available, rendering it suitable to oxidize other molecules (Halliwell et 
al., 2007, Hoidal, 2001).  Reactions involving O2 can result in the generation of reactive 
oxygen species (ROS), including superoxide radicals (O2˙-) and hydroxyl radicals (OH˙), 
as well as non-radicals, including hydrogen peroxide (H2O2), and peroxynitrites (ONOO-) 
(Halliwell et al., 2007, Lambert et al., 2009).   
While low concentrations of ROS are essential for normal cellular function, the 
rapid and excessive generation of ROS along with a decrease in the detoxifying activities 
of intracellular antioxidants poses a danger for cellular survival as ROS can damage 
macromolecular structures including proteins, lipids and nucleic acids (Droge, 2002, 
Halliwell et al., 2007, Hancock et al., 2001, Lambert et al., 2009, Sykes et al., 2007).  The 
imbalance between pro – and antioxidants is commonly referred to as “oxidative stress” 
and has been shown to be elicited following ischemic stroke as well as the subsequent 
reperfusion of brain tissue (Bolanos et al., 2009, Halliwell et al., 2007).  Due to its high 
oxygen consumption and abundant lipid content, the brain is particularly susceptible to 
attack by ROS, which ultimately interferes with normal physiological brain function (Das 
et al., 2007, Pari et al., 2004).   
 
Cellular sources of ROS 
ROS are primarily generated during aerobic cellular respiration at the 
mitochondrial electron transport chain (ETC) (Droge, 2002, Kleinhans et al., 2006, 
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Lambert et al., 2009).  Normally, electrons are transferred by a system of electron carriers 
to O2, the final electron acceptor in the chain, in order to form H2O.  A significant 
proportion of electrons, however, “leaks” from intermediate electron carriers of the ETC  
directly onto oxygen, thereby resulting in the generation of superoxide radicals (O2˙-) 
(Halliwell, 1992, Page et al., 2010).  About <5% of the total electron flow through the 
ETC accounts for electron leakage under physiological conditions (Halliwell, 1992), 
resulting in the formation of 2 billion O2˙- and H2O2 molecules per cell per day in humans 
(Hoidal, 2001).  
 
Targets of ROS: lipids, DNA, proteins 
 Reactive oxygen species can cause serious damage to all cellular macromolecules 
including proteins, lipids and nucleic acids (DNA and RNA).  Damage by ROS has been 
associated with ischemic stroke, neurodegenerative diseases, diabetes and inflammatory 
diseases (Halliwell, 1992, Halliwell et al., 2007, Maisonneuve et al., 2009, Szeto, 2006).  
As a result, understanding the mode of action of ROS on macromolecules is of utmost 
importance in order to identify targets for therapeutic intervention.   
Attack of DNA by ROS does not only result in damage to the purine and pyrimide 
bases and the deoxyribose sugars of DNA, but it also leads to strand breakage and 
interferes with processes including DNA repair, replication and transcription (Halliwell et 
al., 2007, Monaghan et al., 2009).  The process of oxidative damage to lipids is 
commonly referred to as lipid peroxidation and has dramatic consequences for the 
structure, fluidity and function of biological membranes (Fam et al., 2003, Halliwell et 
al., 2007, Milne et al., 2005, Montine et al., 2004, Musiek et al., 2005).  Moreover, lipid 
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peroxidation also results in the formation of biologically active byproducts, such as 
isoprostanes, cytotoxic aldehydes and hydrocarbons, which can subsequently damage 
other cellular components (Fam et al., 2003, Halliwell et al., 2007, Mehta et al., 2007, 
Milne et al., 2005, Monaghan et al., 2009, Montine et al., 2004).  
 
Protein damage by ROS 
 With regard to the attack of ROS on proteins, it has to be noted that in contrast to 
the traditional notion that damage to proteins by ROS is random and non-specific, it has 
become increasingly clear that protein adduction by ROS is a highly selective and 
specific process (Halliwell et al., 2007, Liebler, 2008, Maisonneuve et al., 2009).  80% of 
all proteins are adducted at a single cysteine residue (Liebler, 2008), and amino acid 
residues, such as cysteines, methionines, histidines, arginines and lysines, are particularly 
prone to adduction by ROS (Dennehy et al., 2005, Halliwell et al., 2007, Liebler, 2008).  
Moreover, it has been shown that structural features of proteins, the presence of a 
transition metal as part of the protein structure and the proximity of a protein to the site of 
ROS generation also play important roles in conferring susceptibility of proteins to 
damage by ROS (Liebler, 2008, Maisonneuve et al., 2009).   
Given that proteins are involved in a variety of cellular processes, including, 
amongst others, catalysis of cellular reactions, signal transductions, protein transport and 
receptor function, loss of protein function due to damage by ROS can have a large impact 
on overall cellular function (Dalle-Donne et al., 2003, Halliwell et al., 2007, 
Maisonneuve et al., 2009).  Attack of proteins by ROS can be multimodal.  On the one 
hand, proteins can be directly attacked by ROS, while on the other hand, damage to 
  15 
 
proteins can be of secondary nature via attack of end-products of lipid peroxidation 
(Halliwell et al., 2007, Liebler, 2008).     
A common biochemical marker of protein oxidation is the formation of carbonyl 
groups (aldehydes and ketones) on protein side chains.  Carbonyl groups are composed of 
a carbon atom double-bonded to an oxygen atom, and are primarily formed on proline, 
arginine, lysine and threonine side chains (Dalle-Donne et al., 2003, Levine et al., 1990, 
Levine et al., 1994, Robinson et al., 1999, Shacter et al., 1994).  Moreover, reactive 
aldehydes govern the formation of carbonyl groups on protein side chains including 
lysines, cysteines and histidines (Dalle-Donne et al., 2003, Maisonneuve et al., 2009).  
Protein adduction can irreversibly alter a proteins’ structure and function and result in the 
accumulation of oxidatively modified proteins, a common pathological hallmark 
observed in neurological diseases (Halliwell et al., 2007, Liebler, 2008).  In Chapter III 
we discussed how these attributes allowed us not only to determine total levels of 
oxidized proteins following acute oxidative injury, but also to identify the specific protein 
targets of oxidative stress.  
 
Cellular antioxidant systems 
Cells are equipped with robust cellular antioxidant defense mechanisms to aid in 
the scavenging and removal of ROS.  An antioxidant is “any substance that significantly 
delays or prevents oxidation of that substrate” (Halliwell et al., 2007).  There are a wide 
variety of antioxidants, including those that are synthesized in vivo, such as glutathione, 
catalase and superoxide dismutase (SOD), and those that are supplemented to the body 
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from the diet, such as ascorbic acid (Vitamin C) and alpha-tocopherol (Vitamin E) 
(Halliwell et al., 2007, Hancock et al., 2001).   
The low molecular weight antioxidant glutathione (GSH) is, however, the most 
abundant cellular antioxidant with concentrations ranging between 0.5 and 10mM 
(Maher, 2005).  This tripeptide is synthesized from glutamate, cysteine and glycine via 
the enzymatic activities of glutamate cysteine ligase (GCL) and glutathione synthase 
(GS) (Halliwell et al., 2007, Maher, 2005).  Glutathione peroxidases (GPx) aid in the 
removal of H2O2 in a process that results in the oxidation of GSH, and the generation of 
H2O and glutathione disulfide (GSSG) as reaction products.  In whole cell extracts, the 
percentage of GSSG to GSH lies between 1 and 3%, while in mitochondria this 
percentage is elevated and ranges between 9-25% (Lenton et al., 1999).  GSSG can be 
converted back to GSH with the help of glutathione reductase (Halliwell et al., 2007, 
Maher, 2005) and GSH can also scavenge a wide variety of other ROS, including OH˙, 
hypochlorous acid (HOCl-) and peroxynitrite (ONOO-) (Halliwell et al., 2007). 
 
Cellular Strategies to Handle Protein Stress – Molecular Chaperones 
 Despite the highly efficient role of cellular antioxidants in protecting 
macromolecular structures from the damaging effects of ROS, protein damage may still 
occur.  When ROS overrun cellular defenses, cells rely on tightly regulated endogenous 
surveillance systems to remove injured proteins.  These systems are specialized not only 
in maintaining and controlling proper protein structure and quality, but also in aiding to 
repair and restore proper protein function (Hohfeld et al., 2001, Kaarniranta et al., 2002, 
Voisine et al., 2010).  At the core of the cellular surveillance system, or protein quality 
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control, lie molecular chaperones which are highly conserved, abundantly expressed 
proteins that are present in all cell types, tissues and subcellular compartments (Voisine et 
al., 2010).  Expression levels of molecular chaperones can be regulated by a wide range 
of physiological and environmental stressors, yet a core group of sentinel molecules are 
also constitutively expressed in order to maintain protein homeostasis (Bukau et al., 
2006, Douglas et al., 2010, Ellis et al., 1991, Voisine et al., 2010).   
 
Heat Shock Proteins (HSPs) 
 The heat shock protein (HSP) molecular chaperones form the backbone of the 
protein sentinel system.  They are highly conserved, abundantly expressed proteins with 
diverse functions, including the assembly of multi-protein complexes, transport of 
nascent polypeptides and regulation of protein folding (Hohfeld et al., 2001, Kiang et al., 
1998, Nollen et al., 2002).  Heat shock proteins can be divided into two main classes.  
The first class is composed of HSPs that are constitutively expressed in the tissue and are 
referred to as cognate proteins, while the second class is composed of HSPs that are 
synthesized immediately following stress and are referred to as inducible proteins 
(Snoeckx et al., 2001). The molecular chaperone heat shock protein 70 (HSP70) is the 
major stress inducible cytosolic chaperone and is upregulated with thermal stress, 
oxidative injury, and following acute and chronic injury (Cyr et al., 2002, Hohfeld et al., 
2001).  The HSP70 family has been broadly recognized for its neuroprotective properties 
which have been attributed to the binding and sequestering of activated caspases and 
other cell death proteins by HSP70 as well as to its ability to actively refold damaged 
substrates (Arndt et al., 2007, Beere et al., 2001, McLaughlin et al., 2003).   
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 HSP70 operates as part of a multi-protein complex where associated co-
chaperones alter the function of the complex (FIGURE 1.3) (Arndt et al., 2007, Hohfeld 
et al., 2001, Qian et al., 2006).  For example, the E3 ubiquitin ligase C-terminus of 
HSC70 interacting protein (CHIP) competes with heat shock cognate 70 (HSC70) 
organizing protein (HOP) for C-terminal HSP70 binding, while Bcl-2-associated 
athanogene 1 (BAG-1) competes with HSC70 interacting protein (HIP) for N-terminal 
HSP70 binding (Arndt et al., 2007, Hohfeld et al., 2001).  The formation of the 
HIP/HSP70/HOP complex is thought to direct HSP70 activity towards client protein 
refolding, whereas the CHIP/HSP70/BAG-1 complex promotes client protein 
ubiquitination and subsequent proteasomal degradation (FIGURE 1.3) (Arndt et al., 
2007, Hohfeld et al., 2001).  
FIGURE 1.3:  Schematic presentation of the co-chaperone networks that interact 
with HSP70 to govern protein triage decisions.  The interaction of HSP70 with the 
co-chaperones HIP and HOP results in the refolding of a protein substrate, while 
HSP70‘s interaction with BAG-1 and CHIP governs proteasomal protein degradation. 
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 It has become increasingly clear that HSP70’s association with different co-
chaperone networks also governs HSP70’s ATPase activity, which is located at the N-
terminus of the HSP70 protein (Nollen et al., 2002).  That is, the binding of HIP and HOP 
to HSP70 results in the activation of HSP70’s ATPase activity, promoting the ADP-
bound, high-substrate affinity state of HSP70, thereby supporting the refolding of the 
client protein.  In contrast, binding of BAG-1 and CHIP to HSP70 inhibits the hydrolytic 
activity of HSP70’s ATPase domain, resulting in the ATP-bound, low-substrate affinity 
state of HSP70, promoting the proteasomal degradation of the client protein (Kampinga 
et al., 2003).  Therefore, one would predict that in a state where ATP is limiting, such as 
in ischemic stroke, HSP70’s activity is directed toward the refolding of protein substrates 
as opposed to the tagging of client proteins for subsequent proteasomal degradation.     
 
C-terminus of HSC70 interacting protein (CHIP) 
CHIP discovery and distribution  
 C-terminus of HSC70 interacting protein (CHIP) is a dual function co-
chaperone/E3 ubiquitin ligase with a molecular weight of 34.8kDa (Ballinger et al., 1999, 
Qian et al., 2006).  Using full-length hCHIP fused to the GAL4 DNA-binding domain as 
the bait, CHIP was first identified in 1999 during a yeast-2-hybrid screen aimed at the 
identification of additional proteins that contain a tetratricopeptide repeat (TPR) domain 
(Ballinger et al., 1999).  The TPR domain is a 34-amino-acid protein-protein interaction 
motif that is involved in a variety of cellular functions including protein transport, 
development, transcription and mitosis (Ballinger et al., 1999).  Using Northern blot 
analysis to determine CHIP’s distribution in human tissue as well as its presence in a 
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multitude of commonly used in vitro tissue culture systems, Ballinger and colleagues 
demonstrated that CHIP expression is highest in adult striated muscle and heart, but it is 
also present in brain, placenta, liver, kidneys and lung.  Moreover, CHIP is expressed in 
most human cell lines and primary cultures (Ballinger et al., 1999).   
 
CHIP structure and function 
In addition to the discovery of CHIP, Ballinger and colleagues not only delineated 
parts of the protein structure of CHIP, but also determined the function of some of these 
protein domains (Ballinger et al., 1999).  From a structural perspective, the CHIP protein 
can be divided into three main domains: the N-terminal TPR domain, the mixed charged 
region and the C-terminal U-box domain (FIGURE 1.4) (Ballinger et al., 1999, Jiang et 
al., 2001, Murata et al., 2001).  The N-terminal TPR domain of the CHIP protein governs 
CHIP’s interaction with HSC70, HSP70 and heat shock protein 90 (HSP90) (Ballinger et 
al., 1999).  The highly mixed charged region of CHIP is required for CHIP dimerization 
and proper CHIP function (Nikolay et al., 2004).  The C-terminal U-box domain harbors 
the E3 ligase activity of CHIP, indicating a role of CHIP in the ubiquitination of protein 
substrates thereby targeting them for their subsequent proteasomal degradation 
(FIGURE 1.4) (Jiang et al., 2001, Murata et al., 2001).  Moreover, it has become evident 
that CHIP has autoubiquitination capabilities which are independent of the ubiquitination 
status of client proteins (Jiang et al., 2001, Murata et al., 2001).  Ultimately, it is through 
the E3 ligase activity of the U-box and CHIP's ability to interact with molecular 
chaperones that CHIP has been coined as the link between two of the most opposing 
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cellular systems, namely the molecular chaperone system and the ubiquitin proteasome 
pathway (McDonough et al., 2003).  
 
 
 As previously mentioned, the co-chaperone CHIP interacts with main members of 
the HSP family by means of its N-terminal TPR domain.  The importance of this 
interaction is that the association of CHIP with HSP70 is crucial in governing the fate of 
client proteins due to CHIP’s ability to inhibit HSP70’s ATPase activity.  This interaction 
decreases the time HSP70 is associated with the client substrate thereby enhancing the 
rapid ubiquitination of the client protein by CHIP (Kampinga et al., 2003).  In addition to 
being involved in regulating HSP70’s folding cycle, CHIP also controls HSP70 
expression itself (Kim et al., 2005).  Qian and colleagues demonstrated that CHIP can not 
only enhance HSP70 induction during times of stress, but also decrease HSP70 
expression levels during recovery (Qian et al., 2006).  These processes are predominantly 
governed by CHIP’s interaction with heat shock factor 1 (HSF1), both of which 
translocate from the cytoplasm into the nucleus following stress where they govern the 
FIGURE 1.4:  Protein domain arrangement of CHIP.  The CHIP protein is composed 
of three domains.  The N-terminal tetratricorepeat domain governs CHIP’s interaction 
with main members of the heat shock protein family.  The mixed charged region is 
required for CHIP dimerization.  The C-terminal U-box domain governs CHIP‘s E3 
ubiquitin ligase activities. 
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synthesis of inducible heat shock proteins (Anderson et al., 2009, Dai et al., 2003, Kim et 
al., 2005).  
 
CHIP substrates and its implication in human diseases 
 In addition to CHIP’s role in governing HSP70 folding activities and expression 
levels, CHIP also functions as an E3 ubiquitin ligase, thereby mediating the tagging of 
damaged proteins for their subsequent proteasomal degradation.  In the last decade, a 
wide range of studies were aimed at identifying endogenous substrates of CHIP.  It is 
now known, that CHIP is responsible for the degradation of over 40 proteins including 
tau, α-synuclein, ataxin-3, p53, huntingtin and the cystic fibrosis transmembrane 
conductance regulator (Arndt et al., 2007, Rosser et al., 2007), all of which are associated 
with diseases including Parkinson’s, Alzheimer’s and Huntington’s as well as cystic 
fibrosis and cancer (Arndt et al., 2007, Rosser et al., 2007).   
 Acute overexpression of CHIP can increase cellular survival in vitro via CHIP’s 
ability to aid in the removal of damaged proteins, thereby decreasing proteotoxic stress in 
chronic neurological diseases (Arndt et al., 2007, Dickey et al., 2007, Rosser et al., 2007).  
Specifically, in an elegant study, Imai and co-workers demonstrated that CHIP can 
compensate for the loss of function of the proteotypic E3 ligase Parkin, a protein where 
mutations are associated with an autosomal recessive form of Parkinson’s disease (Imai 
et al., 2002).  These results imply that although E3 ubiquitin ligases are highly specific 
with respect to the client proteins they interact with, a certain degree of redundancy exists 
(Morishima et al., 2008).  This redundancy resulted in a strong push in the Parkinson’s 
disease field to develop drugs and therapies to increase CHIP expression as a means to 
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block Parkinson’s disease induced neuronal dysfunction and death.  This work was, 
however, premature given that the E3 ligase activity of Parkin is highly limited and the 
long-term consequences of increased CHIP expression on cell death were unknown.  
 
Ubiquitin and the Proteasome 
Ubiquitin 
 Given CHIP’s function as an E3 ubiquitin ligase, it is involved in tagging 
damaged proteins for their subsequent proteasomal degradation via the attachment of an 
ubiquitin chain (Jiang et al., 2001, McLaughlin et al., 2005, Murata et al., 2001).  The 
attachment of ubiquitin molecules to a damaged protein is governed by the sequential 
interaction of the E1 activating, E2 conjugating and E3 ligating enzymes (Goldberg, 
2005, Herrmann et al., 2007, McLaughlin et al., 2005).  While there are a handful of E1 
enzymes and a few dozen E2 enzymes, there are 500-1000 E3 ligases present in 
eukaryotic cells (McLaughlin et al., 2005).  This large number of E3 ligases underscores 
that the specificity of the ubiquitin proteasome pathway (UPP) occurs at the levels of the 
E3 ligases (Goldberg, 2005, Herrmann et al., 2007, McLaughlin et al., 2005).  Moreover, 
while the involvement of several of the seven lysine residues of ubiquitin have been 
associated with a variety of cellular functions, ubiquitin’s lysine residue 48 (K48) 
governs the targeting of damaged proteins for their subsequent proteasomal degradation 
(Herrmann et al., 2007, McLaughlin et al., 2005). 
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The proteasome 
 Once ubiquitinated, proteins are processed to the next step in the UPP, namely the 
proteasome (Jiang et al., 2001, Murata et al., 2001).  The 26S proteasome has a molecular 
weight of approximately 2.5MDa and is composed of a 20S core subunit with 19S 
regulatory subunits attached to each side (Hanna et al., 2007).  This ATP-dependent, 
multi-subunit complex is located throughout the cytosol and in the nucleus, and it is the 
major intracellular non-lysosomal proteolytic system essential for the rapid elimination of 
damaged proteins (Coux et al., 1996, Herrmann et al., 2007, McLaughlin et al., 2005).   
 Given the UPP’s role in removing damaged proteins from the cell, a multitude of 
studies have focused on investigating its role in disease states, as the accumulation of 
damaged proteins is a common pathological hallmark of many human diseases including 
ischemic stroke, Parkinson’s disease and Alzheimer’s disease (Goldberg, 2003, Hegde et 
al., 2007, McLaughlin et al., 2005).  Studies in the field of ischemic stroke demonstrate a 
loss in proteasome activity within 10min following the insult, leading to the accumulation 
of damaged and ubiquitinated proteins in the CNS (McLaughlin et al., 2005).  Moreover, 
the use of electron microscopy allowed for the identification of the precise location of 
protein aggregates, demonstrating an accumulation of damaged proteins in the soma, 
dendrites and axons of neurons following ischemic injury (Hu et al., 2000, McLaughlin et 
al., 2005).  In contrast, studies in the field of chronic neurodegenerative diseases suggest 
that an impairment of the UPP may be involved in the development of disease pathology 
(Hegde et al., 2007).  For instance, in the case of Parkinson’s disease, mutations in the E3 
ubiquitin ligase Parkin have been associated with the onset of an autosomal recessive 
form of the disease (Imai et al., 2002).  These mutations abolish the E3 ligase activity of 
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Parkin, preventing the proper ubiquitination of damaged proteins for their subsequent 
proteasomal degradation, and ultimately leading to the accumulation of damaged proteins 
and neuronal death (McLaughlin et al., 2005).   Results like these not only demonstrate 
the importance of the proper function of the UPP for cellular function and survival, but 
also underscore the complexity of this pathway and the crucial role it plays in the CNS.  
 
CHIP – To Be or Not to Be? 
 The overexpression of CHIP has been shown to be neuroprotective in animal and 
cell culture models of chronic neurodegenerative disorders, an effect which has been 
attributed to CHIP’s E3 ligase activity by which damaged proteins are tagged for 
proteasomal degradation (Imai et al., 2002, Sahara et al., 2005).  As a result, increasing 
CHIP expression appears to be a reasonable target for neurotherapeutic intervention in 
chronic neurodegenerative diseases.  However, CHIP’s role in determining cell fate in 
acute neurological disorders has not been assessed.  Moreover, studies investigating the 
ability of the brain to control expression levels of this dual function co-chaperone/E3 
ubiquitin ligase under stress have been lacking.  In order to address these questions, the 
following hypothesis and specific aims were proposed and results in the here presented 
thesis were aimed at answering these questions: 
 
Rationale 
 Due to the fact that the molecular events elicited following ischemic stroke are 
also commonly observed in chronic neurodegenerative diseases, including Parkinson’s 
and Alzheimer’s disease (Choi, 1992, Greene et al., 1996), and the fact that acute CHIP 
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upregulation has been associated with increased cellular survival in the context of these 
diseases (Arndt et al., 2007, Dickey & Patterson et al., 2007, Imai et al., 2002, Rosser et 
al., 2007), we sought to determine if CHIP is altered in acute ischemic stroke and 
examine the consequences of altering CHIP expression on responsiveness to oxidative 
stress.  
 
Hypothesis 
 We hypothesized that the increase in CHIP levels observed in our post-mortem 
human tissue samples is a means of neurons to enhance the removal of damaged proteins 
from the cellular environment and to increase survival as a result.  
 
Specific Aims of the Thesis 
1) Is CHIP expression regulated in response to acute neuronal ischemic injury? 
2) What are the consequences of CHIP overexpression in governing neural fate 
following acute injury? 
3) Who are the proteins targets of oxidative stress in the presence of different levels 
of CHIP? 
4) What are the effects of CHIP on neural survival? 
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CHAPTER II 
 
C-TERMINUS OF HSC70 INTERACTING PROTEIN INCREASES 
FOLLOWING STROKE AND IMPAIRS SURVIVAL AGAINST ACUTE 
OXIDATIVE STRESS 
 
Abstract 
Overexpression of the E3 ubiquitin ligase CHIP has been associated with 
increased survival in models of chronic neurodegenerative diseases.  CHIP has also been 
shown to compensate for the loss of function of the E3 ligase Parkin, of which mutations 
are associated with autosomal recessive forms of Parkinson’s disease.  The role of CHIP 
in acute neurological diseases, however, remained unclear.  Using post-mortem human 
tissue samples, we provide the first evidence that cortical CHIP expression is increased 
following ischemic stroke.  Oxygen glucose deprivation (OGD) in vitro led to rapid 
protein oxidation, antioxidant depletion, proteasome dysfunction and a significant 
increase in CHIP expression.  To determine if CHIP upregulation enhances neural 
survival, we overexpressed CHIP in vitro and evaluated cell fate 24hr following acute 
oxidative stress.  Surprisingly, CHIP overexpressing cells fared worse against oxidative 
injury, accumulated more ubiquitinated and oxidized proteins and experienced decreased 
proteasome activity.  Conversely, using siRNA to decrease CHIP expression in primary 
neuronal cultures improved survival against oxidative stress, suggesting that increase in 
CHIP observed following stroke-like injuries is likely correlated with diminished survival 
and may negatively impact the neuroprotective potential of HSP70. 
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Introduction 
 Strokes are predominately ischemic in nature, comprising 87% of all stroke cases 
(Lloyd-Jones et al., 2009).  The risk of ischemic stroke increases dramatically in 
individuals who are diagnosed with hypertension, cardiovascular disease, diabetes and 
dyslipidemia, as well as in individuals who are obese, physically inactive and smoke 
(Lloyd-Jones et al., 2009).  Despite the efforts to educate the public about stroke risk 
factors and to encourage people to improve their health, stroke remains the third leading 
cause of death in this country and the leading cause of serious, long-term adult disability 
(Lloyd-Jones et al., 2009).   
 In the last 30 years, numerous studies aimed at understanding and identifying 
endogenous cellular and molecular responses elicited following stroke were performed in 
an attempt to develop safe and effective neurotherapeutics.  In the course of this work, we 
have increasingly come to appreciate that HSP70 and CHIP are critical regulators of 
neuronal cell fate following injury.  CHIP is a multifunctional ubiquitin ligase and its 
overexpression has been shown to afford neuroprotection by enhancing HSP70’s client 
degradation activity (Dickey & Patterson et al., 2007).  Other functions of CHIP include 
an ability to act as an autonomous molecular chaperone blocking proteotoxic stress 
(Rosser et al., 2007) as well as a regulator of HSP70 expression (Qian et al., 2006).  
CHIP is also capable of impeding cell death associated with severe endoplasmic 
reticulum (ER) stress (Imai et al., 2002), suggesting that CHIP overexpression may 
positively influence survival against chronic stress.  While HSP70 induction is a common 
feature of chronic and acute neurological injuries, alterations in CHIP expression 
following stress have not been evaluated in acute human neurological disorders.  
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Moreover, the ability of CHIP to alter cell survival following acute ischemic stress has 
not been assessed. 
   In this work, we provide the first evidence that CHIP is upregulated in post-
mortem tissue from patients following TIA or stroke, and we also examined the effects of 
chronic CHIP overexpression on neural survival following acute oxidative injury in vitro.  
We demonstrate that chronic upregulation of CHIP is associated with a loss of 
proteasome activity and increased levels of ubiquitinated and oxidized proteins in neural 
cells following acute oxidative stress.  Cells which had high levels of CHIP also had 
decreased survival in response to oxidative stress, while decreasing CHIP expression 
resulted in increased neuronal survival following acute oxidative injury.  These data 
suggest that long-term elevations of CHIP may be deleterious to survival and a poor 
therapeutic strategy to enhance neuronal outcome in the context of acute neurological 
disease or as a means to decrease cell stress in those at high risk of stroke.    
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Materials and Methods 
Reagents 
XT-MOPS running buffer, Tris/Glycine transfer buffer, Criterion Bis-Tris gels 
and prestained kaleidoscope molecular weight markers were purchased from Bio-Rad 
Laboratories (Hercules, CA).  Membrane blocking solution was from Zymed (San 
Francisco, CA).  Western Lightning Chemiluminescence Reagent Plus was from Perkin 
Elmer Life Sciences, Inc. (Boston, MA) and Hybond P polyvinylidene difluoride (PVDF) 
membranes from GE Healthcare (Piscataway, NJ).  Gel Code Blue Stain Reagent was 
obtained from Thermo Scientific (Rockford, IL).  
For Western blots and immunofluorescence, mouse monoclonal antibody to 
ubiquitinated proteins (Clone Fk2, PW8810) was purchased from Biomol (Plymouth 
Meeting, PA).  Rabbit CHIP (PC711) antibody was purchased from Calbiochem (San 
Diego, CA).  Rabbit HSP40 polyclonal antibody (SPA-400), rabbit HSP70 (HSP72) 
polyclonal antibody (SPA-811), and rabbit HSC70 polyclonal antibody (SPA-816) were 
purchased from Assay Designs (Ann Arbor, MI).  The mouse c-myc (9E10) monoclonal 
antibody (sc-40) was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).  
The mouse GAPDH monoclonal antibody (AM4300) was purchased from Applied 
Biosystems/Ambion (Austin, TX).  
For tissue culture, fetal bovine serum (FBS) was purchased from Hyclone (Logan, 
UT) and Penicillin/Streptomycin was obtained from Cambrex Bio Science (Walkersville, 
MD).  Dulbecco’s Modified Eagle Medium (DMEM, 11995) with high glucose, 
Minimum Essential Medium (MEM, 51200), 0.25% Trypsin – EDTA 1x, trypan blue 
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stain 0.4%, and hygromycin B in PBS 50mg/ml were purchased from Invitrogen 
(Carlsbad, CA).   
Unless otherwise stated, all other chemicals were purchased from Sigma-Aldrich 
(St. Louis, MO).   
 
Post-mortem tissue 
 Dr. Rashad Nagra of the VA West Los Angeles Healthcare Center kindly 
provided human post-mortem samples of cerebral cortex from the Human Brain and 
Spinal Fluid Resource Center.  Three patient categories were developed based on 
neuropathological diagnosis and available clinical data.  Control cerebral cortical samples 
were obtained from subjects with no history of neurological disease and where cause of 
death was cancer without evidence of metastasis of the brain (prostate, breast, bladder 
and non-Hodgkin’s lymphoma) (see TABLE 2.1 for patient data and post-mortem 
interval (PMI)). Transient ischemic attacks (TIAs) or subacute stroke category was 
compiled using patients who had a clinical history of TIAs, but the cause of death in 
these patients was associated with other diseases (chronic obstructive pulmonary disease, 
diabetes mellitus, and congestive heart failure) or accidental death.  These specimens had 
no cortical neuropathological lesions that were classified as being larger than 
microinfarctions or injury to the vasculature.  Thickening of the vascular walls in both 
small and large vessels was evident in several samples.  Sections were matched for 
dissection region with subjects in the stroke category.  The stroke category was 
comprised of patients who had suffered non-hemorrhagic strokes associated with 
occlusion of the middle cerebral artery based on at least two of the following findings: 
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clinical manifestations, imaging, or post-mortem placement of plaques/emboli.  The 
average patient age was 74.3 ± 2.94 years, and the average PMI was equal to or less than 
15h.  
 
 
TABLE 2.1:  Human tissue diagnosis and post-mortem interval (PMI). 
 
Primary neuronal cell culture 
 Primary cortical cultures were prepared from embryonic day 18 Sprague-Dawley 
rats as previously described (McLaughlin & Nelson & Erecinska et al., 1998) with 
adaptations.  Briefly, cortices were dissociated and the resultant cell suspension was 
adjusted to 335,000-350,000 cells/ml.  Cells were plated 2ml/well in 6-well tissue culture 
plates containing one 25mm poly-L-ornithine-coated coverslip per well.  Cells were 
maintained at 37ºC, 5% CO2 in growth media composed of a volume to volume mixture 
1320 79 76Cerebral vascular infarction, chronicF 2528b TIA 
  19   89Strokes, Mini; COPDF 3333 TIA 
  10   75TIA; dementiaF 1718 TIA 
  9   78TIA; Alzheimer's diseaseF 1947 TIA 
  7   76TIA; Mild supranuclear palsyF 2435b TIA 
 1020  71 53Large cerebral infarctionM 3132 Stroke 
  14   81Stroke, middle cerebral arteryF 3968 Stroke 
  10   61Stroke; diabetes mellitusM 2264 Stroke 
  4   82Massive right frontal strokeM 2113 Stroke 
  3   80Stroke; hypertensionF 1714b Stroke 
1520 73 72Congestive heart failureF 3406 Control 
  20   73Breast cancerF 3397 Control 
  16   52Lung CancerM 3371 Control 
  10   91Congestive heart failureF 3346 Control 
  11   76CardiomyopathyM 3565 Control 
Average PMIPMI Average Age AgeDiagnosisSex HSB Number   
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of 84% Ham’s F12-nutrients (11765, Sigma-Aldrich, St. Louis, MO), 8% FBS, 24U/ml 
penicillin, 24µg/ml streptomycin, and 80µM L-glutamine.  Glial proliferation was 
inhibited after two days in culture with 1-2µM cytosine arabinoside, after which cultures 
were maintained in Neurobasal medium (Gibco) containing B27 and NS21 supplements 
(Chen et al., 2008), penicillin and streptomycin. 
 
Neuronal oxygen glucose deprivation (OGD) 
Oxygen glucose deprivation experiments were preformed when cells were at least 
two weeks old (14-20 DIV), at which time point neurons represent at least 95% of these 
cultures as assessed by NeuN and GFAP staining (McLaughlin & Nelson & Silver et al., 
1998).  OGD was performed essentially as described (Gonzalez-Zulueta et al., 2000) by 
complete exchange of media with deoxygenated, glucose-free Earle’s balanced salt 
solution (150mM NaCl, 2.8mM KCl, 1mM CaCl2 and 10mM HEPES; pH 7.3), bubbled 
with 10% H2/85% N2/5% CO2.  Cultures were exposed to hypoxia in an anaerobic 
chamber (Billups-Rothberg) for various durations of time (5-90min) at 37ºC.  Upon OGD 
termination, cells were washed with MEM/BSA/HEPES (0.01% BSA and 25mM 
HEPES) and maintained in MEM/BSA/HEPES/2xN2 (0.01% BSA, 25mM HEPES and 
2xN2) until cell viability was determined 18-24hr later using a lactate dehydrogenase 
(LDH)-based in vitro toxicity assay kit.  Toxicity data were represented as averaged raw 
LDH values.  As a positive control for inducing total neuronal degeneration, cultures 
were exposed to 100µM NMDA and 10µM glycine in MEM/BSA/HEPES/2xN2 for 
60min as we have previously described (McLaughlin et al., 2003).  Data were analyzed 
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by two-way ANOVA followed by Bonferroni post hoc analysis to assess significant 
deviations from control.  
Protein extracts from primary neurons were prepared 24hr following exposure to 
OGD as previously described (McLaughlin et al., 2003).  In brief, plates were placed on 
ice and cells were washed twice with ice cold 1xPBS.  Cells were then scraped from the 
dish using a rubber policeman in 350µl TNEB (50mM Tris-HCl, 2mM EDTA, 100mM 
NaCl and 1% NP-40; pH 7.8) with added protease inhibitor cocktail.  Of this suspension, 
50µl was saved for protein determination, 150µl were resuspended in an equal volume of 
Laemmeli Buffer with ß-mercaptoethanol, heated to 95ºC for 10min, and stored at -20ºC, 
and the remaining 150µl were added into a new Eppendorf tube containing dithiothreitol 
(50mM) (DTT; D9779, Sigma-Aldrich, St. Louis, MO) for the determination of total 
oxidized proteins as described in the OxyBlot methodology below.  Immunoblots probing 
for HSC70, HSP70, HSP40, CHIP, Fk2 and GAPDH were processed as described below.   
 
GSH and oxidized glutathione measurement by high-performance liquid 
chromatography 
 
To determine the consequences of OGD on antioxidant defenses, intracellular 
glutathione (GSH) concentrations were measured by high-performance liquid 
chromatography (HPLC) as previously described (Wang et al., 2008).  Briefly, mature 
neuronal cultures (14-21 DIV) underwent OGD as described above.  Upon treatment 
termination, cultures were extracted with 5% perchloric acid/0.2M boric acid.  Acid-
soluble thiols were derivatized with iodoacetic acid and dansyl chloride and were 
analyzed by HPLC using a propylamine column (YMC Pack, NH2, Waters, Milford, 
MA) and an automated HPLC system (Alliance 2695, Waters).  The GSH and oxidized 
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glutathione (GSSG) concentrations were normalized to the protein contents of the 
samples measured by the Bradford assay (Bio-Rad, Hercules, CA). 
 
Determination of total oxidized protein levels using the OxyBlot methodology 
The OxyBlot Protein Oxidation Detection Kit was purchased from Chemicon 
International (Temecula, CA).  For the determination of total oxidized protein levels, 
neural or neuronal cells were harvested as described below or above, respectively.  To 
prevent protein oxidation from occurring after cell harvest, 50mM DTT was added to 
aliquots designated for the OxyBlot procedure and cell lysates were divided for the 
derivatization reaction containing 2,4-dinitrophenylhydrazine and for the negative control 
reaction containing derivatization control solution.  Samples were stored at 4ºC and run 
within seven days of protein derivatization.  Equal protein concentrations were separated 
using 4-12% Criterion Bis-Tris gels and processed as described in the Immunoblotting 
section below.  Antibodies specific for the detection of oxidized proteins were provided 
by the manufacturer.  Data represent results from at least three independent experiments. 
 
Oxidative stress model of neural injury in HT-22 cells 
HT-22 cells were derived from the immortalized H4 hippocampal murine 
neuroblastoma cell line, and were a generous gift from Pamela Maher (Salk Institute).  
This neural cell line was chosen because HT-22 cells are an excellent, well-characterized 
model of neural oxidative injury (Maher, 2005, Stanciu et al., 2000, van Leyen et al., 
2005).  Due to the lack of functional glutamate receptors, these cells undergo oxidative 
stress induced toxicity upon exposure to glutamate, which blocks glutamate-cystine anti-
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porters in the plasma membrane resulting in glutathione deficiency and oxidative cell 
death (van Leyen et al., 2005).  HT-22 cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) with glutamine, supplemented with 10% FBS and 
penicillin/streptomycin (0.2%).  The CHIP overexpressing cell line, CHIP-6B, which we 
refer to as CHIP OE, was derived by stable transfection with a full-length human CHIP 
cDNA with a myc-tag in a hygromycin resistant vector and has been previously described 
(Wang et al., 2005).  Media for these HT-22 derived neural cells was supplemented with 
50mg/ml hygromycin B.  Cells were grown in 75cm2 cell culture flasks at 37ºC with 5% 
CO2  and passed by trypsinization when the cells’ confluency reached 50-80% (Davis et 
al., 1994).  
 
Immunoblotting  
To determine the effect of chronic CHIP overexpression on expression levels of 
inducible molecular chaperones and levels of ubiquitinated proteins, we performed 
immunoblots on extracts from both neural cell lines that underwent oxidative injury.  For 
the preparation of cell extracts, culture dishes were placed on ice and cells were scraped 
into the medium by using a rubber policeman as described above (McLaughlin et al., 
2001).  The cell suspension was centrifuged at 1,141 x g for 10min.  The pellet was 
gently washed with ice cold 1xPBS, followed by its resuspension in 300µl of TNEB with 
added protease inhibitor cocktail.  Fifty microliters of each sample were reserved for the 
spectrophotometrical determination of protein concentrations using a Bio-Rad Dc Protein 
Assay kit (Hercules, CA).  The remaining cell lysate was added to sample buffer, 
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comprised of an equal volume of Laemmli Buffer (Bio-Rad, Hercules, CA) and ß-
mercaptoethanol (1:19), heated to 95ºC for 10min and stored at -20ºC.  
 Equal protein concentrations were separated using 4-12% Criterion Bis-Tris gels, 
after which proteins were transferred to polyvinylidene difluoride (PVDF) membranes, 
and blocked in methanol for 5min at room temperature.  Following 15min of drying, 
membranes were incubated at 4ºC overnight in their respective primary antibody, which 
was diluted in either 5% nonfat milk in Tris buffer saline (TBS) containing 0.1% Tween 
20 (TBST) or Zymed blocking solution.  Primary antibodies were used at the following 
concentrations: C-terminus of HSC70 interacting protein (CHIP; 1:500), the constitutive 
form of HSP70 (HSC70; 1:2000), heat shock protein 70 (HSP70; 1:1000), heat shock 
protein 40 (HSP40; 1:10,000), glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 
1:10,000), c-Myc (1:10,000) and antibody to ubiquitinated proteins (clone Fk2, 
1:50,000).  The following day, the primary antibody was removed, the membranes were 
washed 4 times with TBST for a total of 30min, and then incubated for 1hr at RT with a 
horseradish peroxidase (HRP)-conjugated anti-rabbit or anti-mouse secondary antibody.  
The membranes were then washed as above and placed into 2ml of ECL 
chemiluminescent substrate for 1min at room temperature.  The membranes were then 
exposed to HyBlot CL Autoradiography Film (Denville Scientific Inc., Metuchen, NJ) 
(McLaughlin et al., 2001).  
 Semi quantitative analyses of immunoblots were performed and were noted per 
our previously described method by performing high resolution scans for densitometric 
quantification with Scion NIH IMAGE J.  Values are expressed as mean increase above 
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control levels (± SEM) and statistical analysis was performed by using two-tailed t tests 
(McLaughlin et al., 2003). 
  
Immunofluorescence 
Cells were fixed in 10% formaldehyde and then permeabilized with 0.1% Triton 
X-100 as we have previously described (Du et al., 2002).  Cells were then blocked with 
8% Bovine serum albumin (BSA) diluted in 1xPBS and incubated in Fk2 (1:200) primary 
antibody diluted in 1% BSA overnight at 4°C.  Cells were then washed with 1xPBS for a 
total of 30min and incubated in the dark in cy-3 anti-mouse (Fk2) secondary antibody 
(1:500) for 60min at RT.  Cells were counterstained with DAPI to visualize nuclei 
(Ravagnan et al., 2001).  After 25min of additional washes, coverslips were mounted and 
fluorescence was visualized with a Zeiss Axioplan microscope equipped with an 
Apotome optical sectioning filter as previously described (Musiek et al., 2006).  Cells 
that were loaded with propidium iodide (PI) were fixed in 10% formaldehyde, 
permeabilized with 0.1% Triton X-100 and counterstained with DAPI to visualize nuclei 
(Ravagnan et al., 2001).  Following 25min of additional washes, coverslips were mounted 
and fluorescence was visualized as described above. 
  
Proteasome measurements 
To determine the consequences of chronic CHIP overexpression on protein 
turnover, the chymotrypsin-like activity of the proteasome was measured by means of 
fluorogenic peptide substrates.  Both neural lines were plated at a density of 100,000 cells 
per well in 6-well plates, and incubated at 37ºC with 5% CO2 overnight.  The following 
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day, cells were exposed to glutamate (3mM) to induce oxidative stress or MG132 
(10µM) to inhibit proteasome activity (van Leyen et al., 2005).  Oxidative stress was 
terminated by placing culture dishes on ice and scraping cells into culture media with a 
rubber policeman.  The cell suspension was centrifuged at 1,141 x g and 4ºC for 10min.  
After removal of the supernatant, the pellet was washed carefully with ice cold 1xPBS, 
followed by its resuspension in 400µl lysis buffer (10mM Tris-HCl, 0.5mM DTT, 5mM 
ATP, 0.035% SDS and 5mM MgCl2, pH 7.8).  Fifty microliters of each sample were 
reserved for a protein assay and the remaining 350µl were used to determine proteasome 
activity.  Addition of 40µM Suc-LLVY-AMC to each sample was followed by a 30min 
incubation in a 37ºC water bath.  The reaction was terminated by adding 13μl ethanol and 
87.5μl ddH2O to quench the substrate.  One hundred microliter-aliquots from each 
sample were then added to a white 96-well plate (Corning Incorporated, Corning NY) in 
quadruplicate.  Fluorescence was measured by using a SpectraFluorPlus plate reader 
(Tecan, Austria) at 360nm excitation, 465nm emission following a three second pre-
measurement delay and a 40µs integration time.  All data represent the mean ± SEM of at 
least three independent experiments.  
For the assessment of the chymotrypsin-like activity of the proteasome in neuron 
enriched primary cultures, neurons were exposed to oxygen glucose deprivation and 
extracts were prepared by placing plates on ice, then carefully washing cells twice with 
ice cold 1xPBS and harvested as above in lysis buffer.  Fifty microliters of each sample 
were reserved for a protein assay.  The remaining 350μl was used for the assessment of 
the chymotrypsin-like activity of the proteasome as described above.  All neuronal data 
represent the mean ± SEM of at least four to seven independent experiments.  
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Glutamate toxicity assay in neural cells 
Both neural cell lines were plated at a density of 30,000 cells per well in 24-well 
plates and allowed to grow at 37ºC with 5% CO2 overnight.  The following day, cells 
were treated by exchanging the medium with 0.5ml media containing glutamate (1, 3, or 
5mM) and glycine (10µM).  Sorbitol (1M) solution was prepared in culture media to 
induce total cell death.  Twenty-four hours following incubation at 37 ºC, cellular 
viability was photodocumented and assessed with an in vitro thiazolyl blue tetrazolium 
bromide (MTT) toxicology assay.  MTT was dissolved in media comprised of Minimum 
Essential Medium, FBS (0.01%), and GlutaMAX (1%) (Hoyt et al., 2000).  Reconstituted 
MTT was added directly to the wells in an amount that was equal to 10% of the media 
volume.  Cultures were returned to the incubator for 4hr allowing reduction of 
tetrazolium salt by living cells.  Cells were then solubilized by a 1:1 addition of 
solubilization solution (10% Triton X-100 plus 0.1N HCl in anhydrous isopropanol) and 
absorbance was measured using a SpectraFluor Plus plate reader (Tecan, Austria) at a 
wavelength of 590nm with a three second pre-measurement delay.  All data represent the 
mean ± SEM of at least three independent experiments.  
 
Transfections of neural cells and primary cortical neurons with CHIP siRNA  
All siRNAs were obtained from QIAGEN Science (Valencia, CA). The CHIP 
siRNA sequence used for experiments in HT-22 cells was 5’-
CCCACTTGTGGCAGTGTACTA-3’.  The CHIP siRNA sequence used for experiments in 
primary neuronal cultures was 5’-CCAGCTGGAGATGGAGAGTTA-3’.  Amaxa reagents 
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for the transfection of primary neurons and HT-22 cells using the nucleofector 
methodology were obtained from Lonza (Cologne, Germany).  
Because of their high transfection efficiency (80-90%), we used HT-22 cells for 
the biochemical determination of optimal CHIP knock-down.  CHIP siRNA transfected 
cells were harvested at 24-72h post transfection and cell extracts were prepared for 
immunoblotting as described above.  
For the transfection of HT-22 cells, the Cell line Nucleofector Kit V (VCA-1001, 
Lonza, Cologne, Germany) was used following manufacturer’s protocol. Briefly, HT-22 
cells were grown to an 80% confluency, then trypsinized and centrifuged at 1,141 x g for 
10min.  The pellet was resuspended in 5ml plating media, cells were counted and 
adjusted to a final concentration of 1x106 cells per nucleofection sample.  Cells were 
compacted by centrifugation at 1.141 x g for 10min, and the pellet was resuspended in 
100µl Cell Line Nucleofector solution.  CHIP siRNA (25nM) and GFP (2µg) were added 
to 97.5µl of cell suspension and electroporated using Nucleofector program U-030.  Cells 
were immediately placed in a 1:15 dilution of Hank’s balanced salt solution (HBSS) and 
re-equilibrated to RT for 10min.  500μl of the cell suspension was transferred into each 
well of a 6-well plate containing 2ml of growth media.  Transfected cells were allowed to 
grow overnight at 37ºC with 5% CO2 after which transfection efficiency was assessed 
using a Zeiss Axiovert 25 microscope equipped with a fluorescent bulb.  All experiments 
using CHIP siRNA were conducted 72hr following transfection, as pilot experiments 
revealed this to be the amount of time needed for optimal knock-down of CHIP 
expression (FIGURE 2.1A).  
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To assess the effect of CHIP knock-down on neuronal viability, primary cortical 
neurons were transfected with CHIP siRNA on the day of the dissection and cells were 
allowed to grow in culture for 72hr (3 DIV) before conducting experiments. (See 
FIGURE 2.1B for verification of decreased neuronal CHIP expression induced by siRNA 
and electroporation optimized to 72hr).  For transfections of primary neurons, the Rat 
Neuron Nucleofector Kit (VCA-1003, Lonza, Cologne, Germany) was used. To increase 
both neuronal survival following transfection and transfection efficiency, the 
manufacturer’s protocol was modified as follows: the pellet formed following neuronal 
dissociation was washed with HBSS and carefully resuspended in 5ml HBSS.  The cell 
suspension was equally divided into two 15ml conical tubes and cells were allowed to 
settle after which the supernatant was carefully removed.  Cells designated for control 
conditions were resuspended in 1.5ml HBSS, whereas cells specified for nucleofection 
were resuspended in 100µl Rat Neuron Nucleofector solution.  Cells were transfected as 
described above using the Nucleofector program O-03.  Upon termination of the 10min 
re-equilibration period, 250µl of the cell suspension was plated into each well of a 6-well 
plate containing 2ml growth media composed of 84% Dulbecco’s Modified Eagle’s 
Medium (DMEM, 11960, Invitrogen, Carlsbad, CA), 8% Ham’s F12-nutrients (11765, 
Sigma, St. Louis, MO), 8% fetal bovine serum, 24U/ml penicillin, 24µg/ml streptomycin, 
and 80µM L-glutamine and maintained at 37ºC with 5% CO2.  Twenty-four hours 
following transfection, cells underwent a complete growth media change into fresh media 
and transfection efficiency was examined as described above.  
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Induction of oxidative injury in primary cortical cultures 
To determine if neurons had altered vulnerability to acute oxidative injury when 
CHIP expression was decreased, young primary neurons (3 DIV) were exposed to 
glutamate (3mM) for 9hr three days (72hr) following transfection with CHIP siRNA.  
Coverslips of CHIP siRNA transfected and control cortical cultures were transferred into 
a 24-well plate containing control or toxicity media.  Oxidative injury was induced by 
exchanging the growth medium with 0.5ml MEM/BSA/HEPES media containing 
glutamate (3mM) and glycine (10µM). Staurosporin (0.5µM) was prepared in 
 FIGURE 2.1:  Optimal CHIP knock-down is achieved 72hr following transfection.  
A) HT-22 cells and B) young primary neurons were transfected with CHIP siRNA using 
the Nucleoporation methodology.  Cells were harvested at various time points post 
transfection and proteins were separated on SDS-PAGE gels and probed with antibodies 
specific for CHIP, HSC70 or GAPDH.  Optimal CHIP knock-down was achieved 72hr 
following transfection in both model systems.  Comparable results were obtained in three 
additional independent experiments.  
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MEM/BSA/HEPES and was used as a positive control for the induction of apoptosis.  
Upon treatment termination, cells were incubated with 0.5ml propidium iodide (10μM) 
(PI, P4170, Sigma-Aldrich, St. Louis, MO) diluted in MEM/BSA/HEPES for 10min at 
37ºC with 5% CO2 after which cells were fixed and counterstained with DAPI and 
mounted as described in the Immunofluorescence section above.  Cell viability was 
assessed by counting the number of neurons that were positive for propidium iodide and 
that showed chromatin condensation using DAPI staining.  
 
Quantification of cell death in siRNA transfected neurons 
The percentage of propidium iodide positive cells in CHIP siRNA transfected and 
control primary cultures following induction of oxidative injury was determined by cell 
counting.  Neurons undergoing cell death were identified by nuclei with chromatin 
condensation as well as by intense propidium iodide staining.  Counts were performed by 
individuals blinded to the treatment conditions.  Three to five fields of view per coverslip 
from a total of 10-12 coverslips per condition were quantified as we have previously 
described (Aizenman et al., 2000).  All data represent the average ± SEM from at least 
three independent experiments.  Statistical significance was determined by a two-tailed 
ANOVA and Bonferroni post hoc analysis.  
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Results 
CHIP levels are increased in human tissue following hypoxic injury 
The overexpression of CHIP has been shown to be neuroprotective in animal and 
cell culture models of chronic neurodegenerative disorders, an effect which has been 
attributed to CHIP’s E3 ligase activity by which damaged proteins are targeted for 
proteasomal degradation (Imai et al., 2002, Sahara et al., 2005).  To evaluate if CHIP was 
altered by acute central nervous system injury, we compared the expression profiles of 
CHIP as well as HSP70 and HSC70 in post-mortem human cerebral cortical tissue 
samples from individuals with no history of neurological injury (Control), with those who 
had a recent history of transient ischemic attacks (TIA) or those who suffered from a fatal 
ischemic stroke (Stroke) due to the occlusion of the middle cerebral artery (FIGURE 
2.2A).  Prior work has demonstrated that both the CHIP and HSP70 proteins are stable 
with post-mortem intervals (PMI) of up to 24hr (Sahara et al., 2005).  Therefore, only 
samples with a PMI shorter than 23hr were included in this study.  Patients were matched 
for PMI and gender with an average age of 74 (see TABLE 2.1).  
Using a total sample size of 5 patients from each group, we observed a significant 
increase in HSP70 expression levels in the cerebral cortex in both TIA and stroke 
samples compared to control tissue (FIGURE 2.2B).  The constitutively expressed form 
of the HSP70 family, HSC70, was not altered and was used as a loading control as 
previously described (McLaughlin et al., 2003).  We also observed a significant increase 
in CHIP expression levels in both TIA and stroke tissue (FIGURE 2.2B). 
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Glutathione levels are decreased and oxidative protein damage is increased 
following neuronal exposure to OGD 
To determine if the observed upregulation of CHIP was neuroprotective in an 
acute injury setting, we moved to a more pliable in vitro model of stroke.  Mature neuron 
enriched cultures were exposed to OGD for 5, 15 or 90min followed by a 24hr recovery 
period.  Representative photomicrographs of neurons exposed to OGD for 5 and 15min 
demonstrate many healthy phase-bright neurons (FIGURE 2.3A, B).  Neurite retraction  
FIGURE 2.2:  Hypoxic injury results in increased expression levels of HSP70 and 
CHIP in human tissue.  A) Post-mortem specimens from patients who had experienced a 
fatal ischemic stroke of the middle cerebral artery (Stroke), history of transient ischemic 
attacks (TIA) or died from causes that were not associated with hypoxia, ischemia or 
neurologically compromised (Control) were probed for HSP70, the constitutively active 
chaperone HSC70 or CHIP.  20µg of protein were run in each lane and blots are 
representative of results obtained from 5 independent sample sets.  B) Alterations in 
protein expression were quantified by performing high-resolution scans for densitometric 
quantification with Scion NIH IMAGE J.  Equal protein loading was ensured by protein 
assays and equal expression of HSC70.  Values are expressed as means (± SEM) of 5 
independent sample groups.  * denotes statistical significance compared to control as 
determined by two-tailed t-test with p < 0.05.  For detailed information on PMI, age, sex 
and cause of death, see TABLE 2.1.
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FIGURE 2.3:  Neuronal exposure to OGD impairs antioxidant defenses and 
increases oxidative protein damage.  Neuron enriched primary cultures were exposed to 
oxygen glucose deprivation (OGD) for 5-90min and cell survival was determined by 
visually inspecting cells under phase-bright microscopy.  Representative 
photomicrographs of cultures 24hr after the termination of A) 5 min or B) 15 min of OGD 
demonstrate many healthy phase-bright neurons with elaborate processes.  Neurons 
exposed to OGD for C) 90min show loss of phase-bright somas and neurite retraction 24h 
after OGD. D) Cell viability was furthermore assessed 24hr following OGD using an in 
vitro toxicology kit measuring the release of LDH from dead and dying neurons.  Data 
demonstrate an increase in cell death as the duration of neuronal exposure to OGD 
increased.  E) Total glutathione levels were measured by the HPLC methodology 24hr 
after termination of OGD.  Results reveal a significant decrease in total glutathione levels 
following OGD.  F) Oxidative protein damage was assessed using the OxyBlot 
methodology 24hr following termination of OGD.  Levels of oxidized proteins increased 
following mild and modest OGD particularly in the 40kDa and 70kDa ranges (arrow), but 
decreased robustly following lethal OGD.  All data is expressed as means (± SEM) of 
four to seven independent experiments run in duplicate.  * represents p < 0.05 using a 
one-tailed ANOVA with Dunnett’s post hoc analysis.  DR, Derivatization Reaction; NC, 
Negative Control. 
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and a loss of phase-bright somas was evident following exposure to OGD for 90min 
(FIGURE 2.3C).  These architectural changes were associated with a loss of viability as 
assessed by the release of the essential cytosolic enzyme lactate dehydrogenase (LDH).  
Neither 5 nor 15min OGD significantly increased LDH levels while 90min OGD induced 
cell death comparable to the 100% neurotoxicity observed in neurons that were exposed 
to 100μM NMDA/10μM glycine for 60min (FIGURE 2.3D) (McLaughlin et al., 2003).  
We decided to use 100μM NMDA to induce total cell death in our neuron enriched 
cultures, as previous studies have shown that exposure of neurons to 50µM NMDA for 
5min is neurotoxic, while exposure to 100µM NMDA results in 100% cell death at 24hr 
(Choi, 1992, McNamara et al., 1990, von Engelhardt et al., 2007).   
Enhanced generation of reactive oxygen species (ROS) due to oxidative stress has 
been implicated in the pathophysiology of many neurological disorders including 
ischemic stroke (Chan, 2001, Mehta et al., 2007).  Cells are able to counteract the 
deleterious effects of ROS under normal conditions via the activity of cellular antioxidant 
defense mechanisms, including the main cellular antioxidant glutathione (Maher, 2005, 
Mehta et al., 2007).  In order to assess if mild ischemic conditions were inducing 
antioxidant stress, we assessed total glutathione levels 24hr following 5, 15 or 90min of 
OGD. We observed a significant depletion of glutathione levels which was exacerbated 
with increasing OGD duration (FIGURE 2.3E). 
We next assessed ROS damage to proteins by detection of protein carbonyl group 
formation (Dalle-Donne et al., 2003) and observed a moderate increase in total oxidized 
protein levels as well as an apparent increase in oxidation levels of proteins in the 40kDa 
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and 70kDa ranges (arrow; FIGURE 2.3F).  We did not, however, observe an increase in 
protein oxidation at the 24hr time point following neuronal exposure to lethal ischemia 
(90’; FIGURE 2.3F).  We believe that this result reflects the unrecoverable nature of this 
insult, inducing massive cell death within hours.  This observation is supported by 
preliminary time course analyses using the OxyBlot methodology (3 and 6hr following 
OGD) where severe OGD resulted in increased protein carbonyl formation (data not 
shown).  
 
Neuronal exposure to OGD increases protein ubiquitination, alters proteasome 
function and moderately increases CHIP expression in vitro   
As an E3 ubiquitin ligase, CHIP plays an important role by intervening after 
protein dysfunction via its ability to ubiquitinate damaged proteins and targeting them for 
proteasomal degradation.  Given the intensity of protein oxidation we observed in 
FIGURE 2.3F, we hypothesized that many of these oxidized proteins were likely to be 
tagged for proteasomal degradation.  We therefore investigated if protein ubiquitination 
was altered following various durations of neuronal exposure to OGD.  Using the Fk2 
antibody, which detects mono– and polyubiquitinated proteins, we observed an increase 
in polyubiquitinated proteins, represented by a dark smear of higher molecular weight 
proteins 24hr after OGD.  There was also a near complete loss of monoubiquitinated 
protein species following 90min OGD, indicating that the majority of the cellular 
ubiquitin has been recruited to damaged proteins (FIGURE 2.4A; arrow).   
 
  50 
 
 
 
 
 
 
 
 
 
FIGURE 2.4:  Neuronal OGD increases protein ubiquitination, alters proteasome 
function and moderately increases CHIP expression in vitro.  Whole cell extracts of 
neuronal cultures were harvested 6hr following exposure to OGD.  Proteins were 
separated by SDS-PAGE gels and probed with antibodies specific to mono- and 
polyubiquitinated proteins (Fk2).  A) Protein polyubiquitination increased with prolonged 
exposure of neurons to OGD while a near complete loss of monoubiquitinated proteins is 
detected following lethal OGD (arrow).  B) Primary cultures were exposed to OGD for 5-
90min, harvested 30min, 3hr, or 24hr following OGD and proteasome activity was 
measured.  Data represent the mean ± SEM for five independent experiments.  * denotes 
statistical significance as determined by two-tailed t-test with p < 0.05.  C) Cells 
harvested 24hr after OGD show that CHIP expression levels are significantly increased 
following mild (5’) OGD while HSP70 expression levels increase robustly following 
lethal (90’) OGD.  Data are taken from representative experiments that were performed 
using at least four independent samples.  D) Alterations in CHIP protein expression were 
quantified by performing high-resolution scans for densitometric quantification with 
Scion NIH IMAGE J.  Values are expressed as means (± SEM) of 3 independent 
culturing sessions.  * denotes statistical significance compared to control as determined 
by two-tailed t-test with p < 0.05.    
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In order to determine if protein degradation was altered, we evaluated the effects 
of mild (5’), moderate (15’), or lethal (90’) OGD on neuronal proteasome activity.  We 
observed that while mild OGD led to enhanced proteasome activity 3hr following the 
initial insult, it returned to baseline levels at 24hr.  Moderate OGD did not affect 
proteasome activity at either time point we assessed, whereas lethal OGD and NMDA 
exposure resulted in a dramatic decrease in proteasome activity 24hr later (FIGURE 
2.4B).  These data support a model in which the proteasome is able to clear damaged and 
ubiquitin-tagged proteins following mild ischemic stress, but protein turnover is 
dramatically impaired by lethal injury.   
As we observed an increase in CHIP and HSP70 expression following TIA and 
stroke in humans, we next sought to determine if these changes were recapitulated in our 
in vitro system.  Twenty-four hours following mild, moderate or lethal OGD, CHIP levels 
were indeed significantly increased (FIGURE 2.4C, D).  Moreover, HSP70 was not 
substantially induced until we moved beyond a 15min exposure which we have shown to 
be the maximal subtoxic period of OGD that these cells can withstand (Legos et al., 
2002) (FIGURE 2.4C).   
 
Chronic CHIP overexpression alters chaperone expression profiles following 
oxidative injury in vitro 
In order to determine if cell viability was enhanced in neural systems exposed to 
acute oxidative stress when CHIP was chronically overexpressed, we moved into the HT-
22 cells which are a neural hippocampal cell line, and a well-characterized model of 
neural oxidative injury (Maher, 2005, van Leyen et al., 2005).  The HT-22 derived neural 
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cell line was generated by placing a CHIP myc construct into the HT-22 cell line.  These 
cells are easy to transfect, reproducibly undergo glutamate induced toxicity and have 
many of the signaling systems essential for mediating ischemic injury (Maher, 2005, van 
Leyen et al., 2005, Wang et al., 2005).  
Given CHIP’s function as a modulator of HSP70 expression and turnover (Qian et 
al., 2006), we first evaluated the effects of stable CHIP overexpression on expression 
profiles of inducible HSPs following acute oxidative injury by exposing neural cell lines 
to glutamate (3mM) or the proteasome inhibitor MG132 (10μM) for 3hr.  We observed 
that HSP40 and HSP90 expression levels remained constant in the presence of glutamate 
in both neural lines while HSP70 levels increased in the HT-22 derived neural line upon 
exposure to glutamate.  Myc and CHIP expression were used as positive controls to 
confirm the presence of the myc-tagged CHIP construct in this cell line (FIGURE 2.5). 
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CHIP overexpression is associated with increased protein carbonyl formation 
following oxidative injury and enhanced baseline polyubiquitination  
Given the extent of CHIP overexpression and HSP70 induction by stress, we next 
sought to determine if neural cells with chronically elevated CHIP levels experience 
alterations in the turnover of oxidized proteins.  We exposed both neural cell lines to 
glutamate (3mM) for 3hr after which cells were harvested and total protein carbonyl 
formation was examined.  Under control conditions, HT-22 derived neural lines exhibited 
an apparent decrease in total protein oxidization compared to control cells.  The presence 
of oxidized proteins increased in both cell types following exposure to glutamate but to a 
greater extent in the CHIP overexpressing cultures (FIGURE 2.6A).   
FIGURE 2.5:  CHIP overexpression alters HSP expression profiles following 
oxidative injury.  Both neural cell lines were treated with glutamate (3mM) or 
proteasome inhibitor for 3hr after which whole cell extracts were harvested and prepared 
for immunoblotting.  Proteins were separated on SDS-PAGE gels and probed with 
antibodies specific to HSP70, HSP40, HSP90, Myc, CHIP or HSC70 as a loading control.  
Exposure to glutamate or the proteasome inhibitor MG132 increased HSP70 levels in the 
HT-22 derived neural lines cells while HSP40 and HSP90 expression levels remained 
constant in the presence of glutamate in these cells.  Immunoblots represent results from 
five independent culturing sessions. 
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FIGURE 2.6: CHIP overexpression increases protein carbonyl formation following 
exposure to glutamate and baseline protein ubiquitination.  A) Both neural cell lines 
were exposed to glutamate (3mM) for 3hr after which whole cell extracts were harvested 
and prepared for OxyBlotting.  Exposure to glutamate results in higher levels of protein 
oxidation in HT-22 derived neural lines.  DR, Derivatization Reaction; NC, Negative 
Control.  B) Both neural cell lines were treated with glutamate (3mM) or proteasome 
inhibitor for 3hr after which whole cell lysates were prepared for immunoblotting.  Equal 
amounts of proteins were separated by SDS-PAGE gels and probed for mono – and 
polyubiquitinated proteins using the Fk2 antibody.  Results show increased levels of 
polyubiquitinated proteins in HT-22 derived lines cells at baseline. Proteasome inhibition 
results in a robust increase in polyubiquitinated protein levels along with a decrease in 
monoubiquitinated proteins (arrow) in both neural lines.  Data represent results from five 
independent culturing sessions. 
 
To determine if oxidized proteins were also being tagged for proteasomal 
degradation, we exposed both neural lines to glutamate (3mM) or the proteasome 
inhibitor MG132 (10μM) for 3hr after which cells were harvested and protein 
ubiquitination was analyzed by immunoblotting using the Fk2 antibody (FIGURE 2.6B).  
We observed increased baseline levels of polyubiquitinated proteins in CHIP 
overexpressing cells represented by a smear of higher molecular weight proteins.  
Exposure of both neural cell types to the proteasome inhibitor MG132 resulted in a robust 
increase in polyubiquitinated proteins along with a decrease in monoubiquitinated protein 
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levels (FIGURE 2.6B; arrow), suggesting that the ubiquitin conjugating machinery in 
both cell lines was highly efficient. 
 
Exposure to oxidative injury results in an increase in ubiquitin inclusion bodies and 
a loss of proteasome activity in CHIP overexpressing cells  
 
We next used immunofluorescence to evaluate the localization and morphology of 
ubiquitinated proteins in control and stressed cells.  There was an appreciable increase in 
Fk2 staining following a 3hr exposure to either proteasome inhibition or oxidative 
challenge.  Moreover, exposure to the proteasome inhibitor MG132 resulted in the 
formation of large, dense, cytosolic ubiquitin inclusion bodies which were predominantly 
localized in close proximity to the nucleus in the HT-22 derived neural lines (FIGURE 
2.7, arrow, inset).  This finding is consistent with the work by Dai et al. and Anderson et 
al. who demonstrate nuclear translocation of CHIP following exposure to stress 
(Anderson et al., 2009, Dai et al., 2003) thereby supporting CHIP’s involvement in the 
stress response via its ability to interact with heat shock factor 1 (HSF1) and ultimately 
resulting in the induction of HSP expression (Dai et al., 2003, Qian et al., 2006).  In 
contrast, small, disperse inclusion bodies were observed in the cytosol of HT-22 cells 
(FIGURE 2.7A, inset).  This staining is consistent with our biochemical assessment of 
the chymotrypsin-like activity of the proteasome in which we observed a significant loss 
of baseline proteasome function in the HT-22 derived neural line (FIGURE 2.7B).  A six 
hour exposure to glutamate reduced proteasome activity equally in both neural lines 
(FIGURE 2.7B).  These data suggest that the chronic overexpression of CHIP decreases 
baseline proteasome activity, which is not toxic, but results in the accumulation of 
damaged proteins within cells. 
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FIGURE 2.7: Exposure to oxidative injury leads to an increase in ubiquitin 
inclusion bodies and a loss of proteasome activity in CHIP overexpressing cells. 
Cells were exposed to glutamate (3mM) for 3hr in the presence or absence of the 
proteasome inhibitor MG132 (10μM).  Immunofluorescence was performed using an Fk2 
antibody (red) to evaluate ubiquitinated proteins alongside DAPI (blue) to stain cell 
nuclei.  The increase in ubiquitin aggregates in stressed cells overexpressing CHIP is 
highlighted with arrows.  B) Both cell lines were exposed to glutamate (3mM) for 6hr and 
the chymotrypsin-like activity of the proteasome was measured using the fluorescent 
substrate Suc-LLVY-AMC. CHIP overexpression results in decreased baseline 
proteasome activity.  Data is expressed as fluorescence per mg protein and represent the 
(± SEM) of six independent experiments performed in quadruplicate.  * denotes statistical 
significance as determined by two-tailed t-test with p < 0.05, n = 6. 
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Chronic CHIP overexpression increases vulnerability to oxidative injury in vitro  
Taken together, these data suggest that neural cells which stably overexpress 
CHIP experience a baseline level of protein turnover inhibition or increased production of 
oxidatively damaged proteins which could alter cell fate in response to acute injury.  To 
test this hypothesis, both cell lines were exposed to extracellular glutamate (1, 3, or 
5mM) and incubated for 24hr.  Cells were visually inspected and death was assessed by 
biochemical viability assays.  Representative photomicrographs were taken 24hr later 
(FIGURE 2.8A-D).  In both cell lines, similar numbers of steady state and mitotically 
active cells were found (Stankowski, Cohen and McLaughlin, unpublished observations), 
were adherent and showed healthy cellular morphology (FIGURE 2.8A, C).  Exposure 
to 3mM glutamate for 24hr increased cell detachment, neural shrinkage and cell death, all 
of which were more pronounced in the HT-22 derived neural line (FIGURE 2.8B, D).  
CHIP overexpression was associated with a 50% decrease in cell viability following 
exposure to glutamate (3mM; FIGURE 2.8E).  
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FIGURE 2.8:  CHIP overexpression increases vulnerability to oxidative injury in 
vitro.  Neural cell lines were treated with glutamate (3mM) for 24hr after which cell 
viability was determined by visually inspecting cells under phase-bright microscopy.  A) 
Photomicrographs of control HT-22 cells B) HT-22 cells exposed to 3mM glutamate for 
24hr, C) HT-22 derived neural control cultures and D) those exposed to 3mM glutamate 
for 24hr.  Note the loss of adherent cells in panels B and D compared to respective 
controls and enhanced neural shrinkage and pyknosis in HT-22 derived cells compared to 
HT-22 cells exposed to glutamate.  E) Both cell lines were treated with increasing 
concentrations of glutamate for 24hr and cell viability was assessed with MTT assays. 
Data are expressed as percent survival compared to the control and represent the mean ± 
SEM of five independent experiments performed in quadruplicate.  * denotes statistical 
significance as determined by two-tailed t-test with p < 0.05, n = 5.  
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Neuronal tolerance to acute oxidative injury is enhanced when CHIP expression is 
silenced  
 
As chronic CHIP overexpression was deleterious to neural survival following 
acute oxidative stress, we next sought to determine if blocking CHIP expression would 
increase neuronal tolerance in this paradigm.  Primary neuronal cultures were transfected 
with CHIP siRNA and a green fluorescent protein (GFP) reporter followed by exposure 
to glutamate (3mM) 72hr later.  The 72hr time point was chosen because pilot 
experiments using CHIP siRNA determined that optimal CHIP protein knock-down in 
primary neurons occurs at this time point (FIGURE 2.1B).  The 30% transfection 
efficiency we achieved with this system made it amenable to immunofluorescence and 
cell counting to assess injury but not to biochemical analysis.  Three days after CHIP 
silencing, neurons were exposed to mild oxidative stress for 9hr followed by incubation 
in propidium iodide to assess neuronal viability.  We observed propidium iodide uptake 
predominately in cells that were not transfected with CHIP siRNA or GFP (FIGURE 
2.9A, arrowheads).  Cell counts revealed that 17% of the non-transfected cells were 
propidium iodide positive under control conditions, while only 1% of neurons in which 
CHIP expression levels were suppressed were positive for propidium iodide (FIGURE 
2.9B).  This suggests that decreasing CHIP expression increases survival following 
electroporation and transfection stress.  Nine hours after exposure to acute oxidative 
injury, there was a significant increase in cells which took up propidium iodide.  Thirty 
percent of non-transfected cells were positive for the cell death marker, whereas 
decreased CHIP levels dramatically improved survival with only 2% of green transfected 
cells also including the red staining of propidium iodide (FIGURE 2.9A).  Taken 
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together, these data suggest that reducing CHIP expression levels renders neurons more 
resistant to acute oxidative injury. 
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FIGURE 2.9:  Decreasing CHIP expression enhances neuronal tolerance to oxidative 
stress.  Primary cultures were transfected with CHIP siRNA upon dissociation and plated. 
After 72hr, cells were exposed to glutamate (3mM) for 9hr followed by incubation in 
propidium iodide (PI, 10μM) for 10min and fixed for immunofluorescent analysis of 
propidium iodide uptake (red) in cells that received CHIP siRNA (green).  See supplemental 
FIGURE 2.1B for verification of decreased CHIP expression in neurons induced by siRNA 
electroporation optimized to 72hr.  B) Quantification of the percent of non-transfected and 
CHIP transfected neurons positive for the cell death marker propidium iodide.  Cell counts 
performed by three independent investigators of >1500 neurons revealed a significant 
decrease in propidium iodide uptake in neurons transfected with CHIP siRNA following 
exposure to acute oxidative stress.  Results represent data from three independent 
experiments.  Data was analyzed by two-tailed ANOVA and Bonferroni post hoc analysis 
performed on a group effect with * represents p <0.05. PI, Propidium iodide. Scale bar = 
100µM. 
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Discussion  
Stroke is the third leading cause of death in the US with 87% of all stroke cases 
being ischemic in nature (Lloyd-Jones et al., 2009, Rosamond et al., 2008).  The cellular 
and molecular mechanisms associated with neuronal death following ischemic stroke 
have been extensively studied.  Yet, we have failed to design effective neurotherapeutics 
that can increase neuronal survival following stroke (Ginsberg, 2008).  While many 
preclinical studies have demonstrated the neuroprotective effects of molecular 
chaperones (Sharp et al., 1999, Yenari, 2002), we are only beginning to understand the 
mechanisms by which protection is afforded.   
The major protective effects of the HSP70 chaperone complex are associated with 
sequestering activated proteases and enhancing protein refolding and degradation (Arndt 
et al., 2007, Beere et al., 2001, Hohfeld et al., 2001).  The ability of cells to monitor the 
folding status of newly synthesized and preexisting polypeptides via the help of HSP70 
and its associated co-chaperone complexes, assures the preservation of protein 
homeostasis and is essential for cellular survival (Arndt et al., 2007, Goldberg, 2003, 
Hohfeld et al., 2001). 
The HSP70 co-chaperone of particular interest is the E3 ubiquitin ligase CHIP.  
This dual-function co-chaperone/E3 ligase has been predominantly studied in the context 
of chronic neurodegenerative diseases, with data supporting a model whereby CHIP 
overexpression provides neuroprotection by enhancing the degradation of damaged 
proteins and by substituting for the loss of other ubiquitin ligases (FIGURE 2.10) (Imai 
et al., 2002, Sahara et al., 2005).  CHIP’s role in governing cell fate in acute neurological 
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disorders as well as the ability of the brain to regulated CHIP expression following 
ischemic injury have, however, not been assessed up until now.   
Our results are the first evidence that CHIP expression levels are increased in the 
human cerebral cortex following ischemic stroke.  Yet, when moving into our neuronal in 
vitro model system, which provides a reproducible and accessible platform to mimic 
biological components seen in TIA and stroke, we found that the degree of CHIP 
upregulation was not as pronounced as in the human tissue samples.  This observation 
may be due to the fact that we used neuron enriched cultures for our OGD experiments, 
which allow us to better detect neuronal CHIP expression levels as compared to the 
human tissue samples which include neurons and glia.  Due to our concern that we would 
not be able to fully capture the molecular effects of CHIP upregulation on cell fate, we 
moved into the HT-22 neural cell line which allowed us to stably drive CHIP expression 
at high levels.   
The HT-22 neural cells were chosen for our studies because they have been used 
extensively to model oxidative injury (Luo et al., 2006, van Leyen et al., 2005).  The 
absence of functional NMDA receptors in these cells makes for a near pure oxidative 
insult versus a mixed oxidative and excitotoxic insult (Luo et al., 2006, Maher, 2005, van 
Leyen et al., 2005).  In this model, the addition of extracellular glutamate blocks the 
glutamate-cystine anti-porter in the plasma membrane, subsequently leading to the loss of 
the intracellular antioxidant glutathione (Luo et al., 2006, Maher, 2005, van Leyen et al., 
2005).   
While we initially hypothesized that increasing CHIP would be neuroprotective, 
we observed quite the opposite.  Although we did not observe significant alterations in 
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baseline GSH or GSSG levels in our cell lines (data not shown), we found that chronic 
CHIP overexpression was associated with decreased proteasome function, increased 
protein inclusion formation, increased levels of total oxidized proteins and poor survival 
following acute oxidative injury (FIGURE 2.10).  Increased protein ubiquitination and a 
loss of proteasome activity have also been reported following ischemic stress in animal 
models, but they have never been linked to increases in expression levels of CHIP or 
other E3 ligases (Keller et al., 2000).  We hypothesize that the increased accumulation of 
ubiquitinated and oxidized proteins observed in CHIP overexpressing cells is linked to 
either increased substrate generation or decreased substrate turnover.  We favor a model 
in which CHIP overexpression leads to a physiological overload of polyubiquitinated 
proteins, thereby resulting in decreased substrate cleavage as CHIP-tagged substrates 
compete with the fluorogenic proteasome substrate Suc-LLVY-AMC for access to the 
proteasome.  Our data furthermore support a model in which CHIP overexpression may 
fundamentally alter baseline proteasome activity.  Moreover, by moving to primary 
neuronal cultures, we found that short-term silencing of CHIP significantly decreases 
vulnerability to oxidative stress. 
 
 
 
 
 
 
 
  65 
 
 
 
 
Taken together, this work is the first evidence that CHIP expression levels are 
elevated in the cerebral cortex of patients following ischemic stroke.  While our post-
mortem tissue samples are an excellent means to investigate the effects of ischemic 
stroke on the expression levels of CHIP, we do not know the exact time point at which 
CHIP expression is highest following a lethal ischemic insult, and we also do not know 
how the presence of other risk factors for stroke influence CHIP expression in humans.  
Moreover, we have a poor understanding of how CHIP expression levels change in 
patients who have suffered from either TIA or stroke and survived.  Given the plethora of 
molecular events that are elicited in the days following the initial ischemic insult, it 
would be very intriguing to determine how long following a TIA or stroke CHIP levels 
FIGURE 2.10:  Effects of acute versus chronic CHIP overexpression on cell survival. 
Acute CHIP overexpression results in increased cellular survival due to CHIP‘s ability to 
remove damaged proteins from the cell, while chronic CHIP overexpression results in 
decreased cellular survival due to decreased protein turnover.      
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remain high and if CHIP levels are upregulated in individuals who are at high risk for 
stroke.  Knowing if a correlation between increased CHIP expression levels and 
increased risk for stroke exists would allow scientists to determine if lowering CHIP 
expression levels would decrease the likelihood of high risk patients to suffer from the 
actual ischemic insult. 
Given the lack of availability of not only methodologies that allow for the 
detection of CHIP expression levels in human CNS but also national stroke banks that 
would allow scientists to gather information about CHIP expression profiles from 
multiple post-mortem time points, scientists have to rely on model systems to study 
stroke.  In our case, we relied on our neuronal in vitro model system of OGD and the HT-
22 neural cell line to investigate the effects of elevated CHIP levels on neuronal survival 
following acute stress.  Given that CHIP levels did not increase as robustly in our 
neuronal in vitro model as they did in the human tissue samples, we took advantage of 
the HT-22 neural cell line.  The HT-22 model system allowed us to drive CHIP 
expression at high levels and to investigate the effects of chronic CHIP upregulation on 
neural survival following a pure oxidative insult. For the first time, this showed that 
chronic CHIP overexpression impairs neural survival following oxidative stress.  While 
the HT-22 model system lacks several of the biological features of stroke as described in 
Chapter I, it provides us with a unique opportunity to identify early protein targets of 
oxidative stress in neural cells in order to not only establish if these proteins are potential 
CHIP clients, but also investigate if these oxdiatively modified proteins play a role in the 
pathology underlying stroke.  In the work described in Chapter III, we present a novel 
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and powerful methodology that allows for the identification of these specific protein 
targets of oxidative stress.   
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CHAPTER III 
 
ANALYSIS OF PROTEIN TARGETS BY OXIDATIVE STRESS USING THE 
OXYBLOT AND BIOTIN-AVIDIN-CAPTURE METHODOLOGY 
 
Abstract 
Carbonyl group formation on protein side chains is a common biochemical 
marker of oxidative stress and is frequently observed in acute and chronic neurological 
diseases including stroke, Parkinson’s and Alzheimer’s disease.  We recently reported 
that the levels of total oxidized proteins are elevated in primary neurons following 
exposure to oxygen glucose deprivation, as well as in CHIP overexpressing cells 
following exposure to acute oxidative stress.  Given the importance of proper protein 
function for cellular survival, it is critical to determine how oxidative stress can alter 
protein structure and function and how these damaged proteins contribute to disease 
pathology.  In contrast to the traditional notion assuming that protein modification by 
reactive oxygen species is a random process, it has become increasingly clear that protein 
modifications by reactive oxygen species are specific and selective.  In this work, we 
present two approaches that allow for the detection of protein carbonyl groups.  The 
OxyBlot methodology allows for the evaluation of general oxidative stress, while the use 
of the novel and powerful biotin-avidin-capture methodology allows for the identification 
of specific proteins that have been targeted by oxidative stress.  
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Introduction 
A common biochemical marker of protein oxidation is the formation of protein 
carbonyl groups (aldehydes and ketones) on protein side chains, particularly on prolines, 
arginines, lysines and threonines (Dalle-Donne et al., 2003, Levine et al., 1990, Liebler, 
2008, Robinson et al., 1999, Stadtman, 2006).  Protein adduction by reactive oxygen 
species (ROS) can not only irreversibly alter protein structure and function, but also 
result in polypeptide fragmentation and protein-protein cross linkage (Liebler, 2008, 
Stadtman, 2006).     
Due to the damaging effects of ROS on protein structure and function as well as 
the fact that the accumulation of oxidatively modified proteins is a desirable means to 
evaluate cell stress, several techniques have been developed that allow investigators to 
determine both the levels of total oxidized proteins and the identity of adducted proteins.  
This is particularly salient given that until recently, protein adduction by ROS was 
thought to be a random process (Liebler, 2008).  It has, however, become increasingly 
clear that protein adduction by free radicals is a selective and specific process and that 
approximately 80% of all proteins are modified at a single cysteine residue only (Liebler, 
2008).   
Using our primary neuronal in vitro model system of oxygen glucose deprivation 
(OGD) as a pliable platform to mimic the biological components seen in TIA and stroke 
in combination with the OxyBlot methodology to derivatize protein carbonyl groups, we 
demonstrated that the levels of total oxidized proteins are elevated following mild or 
moderate OGD.  While this model system captures the many biological features of 
ischemic stroke, we were interested in investigating the effects of a pure oxidative insult 
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on protein oxidation status.  For this, we moved into the HT-22 neural cell line, as 
exposure of these cells to extracellular glutamate results in pure oxidative stress (Maher, 
2005, Stankowski & Zeiger et al., 2010, van Leyen et al., 2005).   
Using the OxyBlot methodology, we reported in Chapter II that HT-22 cells 
which chronically overexpress the E3 ligase CHIP accumulate higher levels of total 
oxidized proteins following acute injury.  While valuable, this technique does not allow 
for the identification of the specific protein targets of oxidative stress.  Using the biotin-
avidin-capture methodology as a means to identify specific protein targets of oxidative 
stress, we found that tau, a highly abundant and well known protein target of oxidative 
stress (Dias-Santagata et al., 2007, Egana et al., 2003, Goldbaum et al., 2002, Melov et 
al., 2007, Poppek et al., 2006, Vanhelmont et al., 2010, Zhu et al., 2000), was heavily 
oxidized in CHIP overexpressing cells upon exposure to glutamate.  The detection of tau 
was used as a proof-of-principle showing that this novel technique is applicable to our in 
vitro model system as it has predominantly been used to test protein damage triggered by 
exogenous applications of toxic chemicals, including 4-hydroxy-2-nonenal (4-HNE) 
(Codreanu et al., 2009, Liebler, 2008).  Ultimately, the biotin-avidin-capture 
methodology offers the potential to determine which specific proteins are oxidatively 
modified.  This in turn will allow investigating if these proteins are potential CHIP clients 
and if proteins that are modified by oxidative stress play a role in the pathology 
underlying stroke.    
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Principles of the OxyBlot methodology 
The chemical reaction underlying the OxyBlot methodology was initially 
described by Shacter’s group in 1994 (Levine et al., 1994) and has been extensively 
employed thereafter (Dalle-Donne et al., 2003, Robinson et al., 1999, Shacter et al., 
1994).  Carbonylated proteins are relatively stable, which allows the derivatization of 
carbonyl groups with 2,4-dinitrophenylhydrazine (DNPH) resulting in the formation of a 
stable dinitrophenyl (DNP) hydrazone product (FIGURE 3.1).  The subsequent 
separation of oxidatively modified proteins by electrophoresis followed by the 
identification of the DNP moiety of the protein (FIGURE 3.1) using the Western blot 
technology and anti-DNP antibodies allows for the rapid and highly sensitive 
determination of total protein carbonyl formation (Dalle-Donne et al., 2003, Levine et al., 
1994, Robinson et al., 1999, Shacter et al., 1994).   
The use of the derivatization control solution (negative control) allows for a side-
by-side comparison of proteins that have and have not been oxidatively modified.  
Specifically, bands that are present in the derivatization reaction, but are absent in the 
negative control reaction, have undergone modifications.  Moreover, with the use of 
proper controls, the overall intensity of the bands correlates to the overall degree of 
protein oxidation.  That is, the more intense the bands are, the more oxidized proteins are 
present in a given sample.  
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FIGURE 3.1: Schematic of the derivatization of protein carbonyl groups. Cellular 
exposure to stress results in protein damage characterized by the formation of protein 
carbonyl groups (red side chains). The OxyBlot methodology uses 2,4-
dinitrophenylhydrazine (DNPH) to derivatize protein carbonyl groups leading to the 
formation of a stable dinitrophenyl (DNP) hydrazone product. The primary antibody is 
directed against the DNP moiety of the protein. The secondary, HRP-conjugated 
antibody, allows for the use of chemiluminescent reagents to visualize bands of oxidized 
proteins upon exposure to film.  
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Materials for OxyBlot procedure 
All materials required for the OxyBlot procedure are listed below.  It should be noted that 
similar products and equipments may be used from alternate vendors at the user’s 
discretion. 
1. The OxyBlot Protein Oxidation Detection Kit (S7150) was purchased from 
Chemicon International (Temecula, CA). The mixture of standard proteins with 
attached DNP residues should be stored at -20ºC after the first use. All other 
reagents can be stored at 4ºC. 
2. 6-well tissue culture plates.  
3. 1.5ml Eppendorf tubes. For each condition, the following pre-labeled Eppendorf 
tubes are needed: 
a. Sample for protein assay  
b. Sample for Western blotting 
c. Sample for OxyBlot  
d. Derivatization reaction for OxyBlot 
e. Negative control for OxyBlot 
4. Ice cold 1xPBS (100ml 10xPBS; 900ml milliQ H2O) 
5. TNEB (50mM Tris-HCl, 2mM EDTA, 100mM NaCl and 1%NP-40; pH 7.8) with 
added protease inhibitor cocktail (P8340, Sigma-Aldrich, St. Louis, MO). 
6. Dithiothreitol (DTT; D9779, Sigma-Aldrich, St-Louis, MO). Prepare a 1M stock 
solution in milliQ H2O and store at -20ºC. The working concentration of DTT is 
50mM and should not be stored for more than 6hr.  
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7. Laemmeli Buffer (Cat # 161-0737, Bio-Rad Laboratories, Hercules, CA) with ß-
mercaptoethanol (M7154, Sigma-Aldrich, St. Louis, MO) at a ratio of 1:19.  
8. 12% sodium dodecyl sulfate made in milliQ H2O (SDS; L3771, Sigma-Aldrich, 
St. Louis, MO). 
9. Bio-Rad Dc Protein Assay kit (Bio-Rad Laboratories, Hercules, CA). 
 
Materials for the Western blot procedure 
1. 4-12% Criterion Bis-Tris gels (Cat # 345-0123, Bio-Rad Laboratories, Hercules, 
CA). 
2. Precision Plus Protein Standard All Blue Molecular Weight Marker (Cat # 161-
0373, Bio-Rad Laboratories, Hercules, CA). 
3. XT-MOPS running buffer (Cat # 161-0788, Bio-Rad Laboratories, Hercules, CA). 
4. 1xTris/Glycine transfer buffer (Cat # 161-0772, Bio-Rad Laboratories, Hercules, 
CA). 
5. Hybond P polyvinylidene difluoride (PVDF) membrane (Cat # RPN303F, GE 
Healthcare, Piscataway, NJ). 
6. Western Lightning Chemiluminescence Reagent Plus (Cat # NEL105, Perkin 
Elmer Life Sciences, Inc., Boston, MA). 
7. Gel Code Blue Stain Reagent (Cat # 24592, Thermo Scientific, Rockford, IL). 
8. Methanol (439193, Sigma-Aldrich, St. Louis, MO). 
9. Tween 20 (P7949, Sigma-Aldrich, St. Louis, MO). 
10. 1xPBS-Tween 20 (0.05% Tween 20). 
11.  Blocking/Dilution buffer (1%BSA/PBS-Tween 20). 
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12.  Primary Antibody: Rabbit Anti-DNP antibody (provided in OxyBlot kit). 
13.  Secondary Antibody: Goat Anti-Rabbit IgG (HRP-conjugated) antibody 
(provided in OxyBlot kit).     
 
Methods 
 
OxyBlot procedure using 5µl of each sample 
 
1. Start by scraping cells from the dish using a rubber policeman in 350µl TNEB 
with added protease inhibitor cocktail. For each condition, cells grown in two 
wells of a 6-well plate are combined. A protein concentration of 1mg/ml is 
recommended for the OxyBlot methodology.   
2. Of this cell suspension, save 50µl for the determination of protein concentrations 
and resuspend 150µl in an equal volume of Laemmeli Buffer with ß-
mercaptoethanol.  Heat sample to 95ºC for 10min and store at -20ºC.  During 
preliminary experiments, it was noted that the concentration of DTT used for the 
OxyBlot procedure was not compatible with most standard protein assays.  As a 
result, we decided to remove a 50μl aliquot from the cell suspension for the 
determination of protein concentrations.   
3. Add the remaining 150µl of the cell suspension into a new Eppendorf tube 
containing dithiothreitol (DTT, 50mM) and vortex sample briefly.  Ideally, it is 
best to perform the OxyBlot reaction (FIGURE 3.2) directly after lysing the cells.  
However, samples containing 50mM DTT may be frozen at -20ºC.  For best 
results, do not store samples for more than one month.   
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4. For the OxyBlot procedure, follow the flow chart outlined in FIGURE 3.2.  In 
brief, 5µl of the cell lysate designated for the OxyBlot procedure as well as 5µl 
12% SDS should be added into two new Eppendorf tubes, of which one is 
designated for the derivatization reaction (DR) and the other one for the negative 
control (NC).  Next, add 10µl of 1x 2,4-dinitrophenylhydrazine (DNPH) or 1x 
derivatization control solution into the 1.5ml Eppendorf tubes designated for the 
derivatization reaction or negative control, respectively.  The sample for the 
derivatization reaction takes on an orange color following the addition of 2,4-
dinitrophenylhydrazine.  For the OxyBlot procedure more than 5μl of cell lysates 
per reaction tube may be treated, but the volumes of the other reagents have to be 
adjusted accordingly.  For instance, if 10μl of cell lysate are used, double all 
reagent volumes (i.e., 10μl 12% SDS, 20μl 1xDNPH solution, 20μl 1x 
derivatization solution, 15μl neutralization solution).  This allows for running two 
Western blots probing for oxidized proteins from the same sample.  Moreover, in 
order to prevent an artificial increase in protein carbonyl content in the samples, 
do not allow samples to stand in the derivatization solution for more than 15-
20min (Levine et al., 1994).          
5. Allow samples to incubate at room temperature for 15min after which 7.5µl of the 
neutralization solution should be added to each sample. 
6. Store samples at 4ºC and run samples on a gel within seven days of protein 
derivatization.  Alternatively, samples can be aliquoted and stored at -20ºC.  
Samples should be allowed to reach room temperature prior to immunoblotting. 
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FIGURE 3.2: OxyBlot methodology flow-chart.  Five μl sample are added to two pre-
labeled 1.5ml Eppendorf tubes, of which one is designated for the derivatization reaction 
(DR) and the second one for the negative control (NC).  Five μl of 12% SDS are added to 
each sample to obtain a final concentration of 6% SDS.  Ten μl of 1xDNPH or 1x 
derivatization control solution should be added to samples designated for the derivatization 
reaction or negative control, respectively.  Samples are allowed to incubate for 15min at 
room temperature, after which 7.5μl neutralization solution should be added to each sample.  
Samples are ready to be processed using gel electrophoresis.  
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Western blotting 
 
1. Allow OxyBlot samples to reach room temperature prior to loading samples on a 
gel. Do not heat samples.  
2. For best results, use a gradient gel (e.g., 4-12%). 
3. Start loading the gel by adding 10µl of the Precision Plus Protein Standard All 
Blue Molecular Weight Marker. 
4. Assuring equal protein concentrations of all samples, load the appropriate volume 
of the OxyBlot samples so that the sample of the derivatization reaction is next to 
the sample of the negative control. This allows for a more efficient comparison of 
bands during analysis.  To assure equal protein loading, use samples prepared for 
Western blot analysis and run gels probing for HSC70, GAPDH or any other 
commonly used loading control.   
5. Follow manufacturer’s directions to run the gel. 
6. Transfer proteins onto a PVDF membrane by following manufacturer’s directions 
for the used transfer apparatus.  
7. Block non-specific primary antibody binding by placing the membrane into 
methanol for 5min. 
8. Allow membrane to dry for 15-20min before placing it into primary antibody.  
9. Prepare 15ml of a 1:150 dilution of the primary antibody provided in the OxyBlot 
kit in blocking/dilution buffer.  Preliminary experiments determined that the 
primary antibody provided in the OxyBlot kit cannot be reused.  For best results, 
prepare new primary antibody for each Western blot.   
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10. Incubate the membrane in the primary antibody over night at 4ºC while shaking 
on an orbital shaker. 
11. Using multiple changes of 1xPBS-Tween 20, wash membrane for a total of 30min 
before adding the secondary antibody.  
12. Prepare 15ml of a 1:300 dilution of the secondary antibody provided in the 
OxyBlot kit in blocking/dilution buffer.  
13. Incubate membrane for 1hr at room temperature while shaking on an orbital 
shaker. 
14. Using multiple changes of 1xPBS-Tween 20, wash membrane for a total of 30min 
before adding the chemiluminescent reagent according to manufacturer’s 
specifications and exposing the membrane to film. 
 
Interpretation of data 
1. All biological samples have oxidized proteins with higher levels of total protein 
oxidation in samples following biological stress. 
2. The final result of the OxyBlot procedure shows several bands in the 
derivatization reaction sample of each condition (FIGURE 3.3).  Bands that are 
present in the derivatization reaction but not in the negative control have 
undergone oxidative modifications.  It has been determined that longer exposure 
times of the membrane are required in order for bands in the negative control 
reaction to appear.  Exposure times of up to 15min have been required in order to 
see bands in the negative control reactions.   
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3. The degree of protein oxidation can be identified by the intensity of the bands. 
That is, the more intense the bands are, the higher the degree of stress specific 
protein oxidation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Principles of the biotin-avidin-capture methodology 
 
The biotin-avidin-capture methodology combined with immunoblotting is a 
powerful new technology that allows for the detection of specific proteins that have been 
modified by oxidative stress.  This methodology uses biotin hydrazide to covalently label 
carbonyl groups that have formed on protein side chains upon exposure to oxidative 
stress (FIGURE 3.4).  Using immunoprecipitation, adducted proteins bound to biotin 
hydrazide are pulled down allowing for the elution of oxidatively modified proteins.  The 
FIGURE 3.3: Neuronal exposure to OGD results in protein oxidation.  Mature 
neuron enriched primary forebrain cultures were exposed to oxygen glucose deprivation 
(OGD) for various durations of time (5’, 15’ or 90’) and protein oxidation was 
determined using the OxyBlot methodology 24hr following termination of OGD.  Levels 
of total oxidized proteins increased robustly following mild (5’) or moderate (15’) OGD, 
but decreased strongly following exposure to lethal (90’) OGD.  DR, Derivatization 
Reaction; NC, Negative Control. 
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subsequent immunoblotting analysis allows for a rapid screening of proteins of interest to 
determine if these proteins have been oxidized (FIGURE 3.5) (Codreanu et al., 2009).  
  
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.4:  Schematic of the biotin-avidin-capture methodology.  Exposure of HT-22 
cells to extracellular glutamate results in the depletion of the main intracellular antioxidant 
glutathione and the elevation of ROS levels.  Protein damage by ROS results in the formation 
of carbonyl groups on protein side chains (blue side chain) which are derivatized with biotin 
hydrazide (formation of green double bond).  The addition of sodium borohydride reduces 
the initial Schiff base formed between the carbonyl and biotin hydrazide (formation of purple 
single bond), thus preventing the reversion of the adduct.  The oxidative status of proteins of 
interest can then be analyzed by using the Western blot methodology.  Although the addition 
of extracellular glutamate is used to induce oxidative stress in the HT-22 model system, 
interfering with glutathione synthesis at any other step or directly adding reactive oxygen 
species to the cells are equally effective means to induce oxidative stress.   
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Materials for the biotin-avidin-capture methodology 
 
1. 1.5ml clear Eppendorf tubes. 
2. Ice cold 1xPBS (100ml 10xPBS; 900ml milliQ H2O). 
3. TNEB (50mM Tris-HCl, 2mM EDTA, 100mM NaCl and 1%NP-40; pH 7.8) with 
added protease inhibitor cocktail (P8340, Sigma-Aldrich, St. Louis, MO). 
4. Bio-Rad Dc Protein Assay kit (Bio-Rad Laboratories, Hercules, CA). 
5. MilliQ H2O. 
6. Dimethyl sulfoxide (DMSO; D8418, Sigma-Aldrich, St. Louis, MO). 
FIGURE 3.5:  Tau is oxidized in HT-22 cells.  To induce oxidative stress, HT-22 and 
CHIP OE cells were exposed to glutamate (3mM) for 24hr after which cells were 
harvested, protein concentrations were determined and oxidized proteins were 
immunoprecipitated using the biotin-avidin-capture methodology.  Neither HSC70 nor 
GAPDH are oxidized in this cell line even after prolonged exposure to glutamate.  The 
microtubule-associated protein tau and CHIP substrate is highly oxidized in CHIP OE 
cells (Band in ‘eluate’ lane).  In, Input; E, Eluate; FT, Flow through.  
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7. Biotin hydrazide (B3770, Sigma-Aldrich, St. Louis, MO).  Prepare a 50mM stock 
solution in DMSO and prepare freshly before every experiment. The final 
concentration of biotin hydrazide per sample is 5mM.  
8. Sodium borohydride (213462, Sigma-Aldrich, St. Louis, MO). Prepare a 500mM 
stock solution in milliQ H2O and prepare freshly before every experiment. The 
final concentration of sodium borohydride is 50mM.  
9. NuPAGE LDS Sample Buffer (4x) (NP0007, Invitrogen, Carlsbad, CA). 
10. Amicon Ultra Centrifugal Filter Devices (UFC801024, Millipore, Billerica, MA). 
11. Streptavidin Sepharose High Performance Beads (17-5113-01, GE Healthcare, 
Uppsala, Sweden).  
12. 1% sodium dodecyl sulfate (SDS; L3771, Sigma-Aldrich, St. Louis, MO). 
13. 1M sodium chloride (NaCl; S9525, Sigma-Aldrich, St. Louis, MO). 
14. Dithiothreitol (DTT; D9779, Sigma-Aldrich, St-Louis, MO). Prepare a 1M stock 
solution and store at -20ºC. The working concentration of DTT is 50mM and 
should not be stored for more than 6hr.  
15. 4M urea (U6504, Sigma-Aldrich, St. Louis, MO). Urea has to be freshly prepared 
before every experiment.  
 
 Materials for the Western blot procedure  
 
1. 4-12% Criterion Bis-Tris gels (Cat # 343-0123, Bio-Rad Laboratories, Hercules, 
CA). 
2. Precision Plus Protein Standard All Blue Molecular Weight Markers (Cat # 161-
0373, Bio-Rad Laboratories, Hercules, CA). 
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3. XT-MOPS running buffer (Cat # 161-0788, Bio-Rad Laboratories, Hercules, CA). 
4. 1xTris/Glycine transfer buffer (Cat # 161-0772, Bio-Rad Laboratories, Hercules, 
CA). 
5. Hybond P polyvinylidene difluoride (PVDF) membrane (Cat # RPN303F, GE 
Healthcare, Piscataway, NJ). 
6. Western Lightning Chemiluminescence Reagent Plus (Cat # NEL105, Perkin 
Elmer Life Sciences, Inc., Boston, MA). 
7. Gel Code Blue Stain Reagent (Cat # 24592, Thermo Scientific, Rockford, IL). 
8. Methanol (439193, Sigma-Aldrich, St. Louis, MO). 
9. Tween 20 (P7949, Sigma-Aldrich, St. Louis, MO). 
10. 1xTBS-Tween 20 (100ml 10 x TBS, 900ml milliQ H2O, 0.05% Tween 20). 
11. Carnation Instant Non-Fat Dry Milk Powder (Nestlé, Vevey, Switzerland). 
12. Primary antibodies: Rabbit Anti-HSC70 (SPA-816; Stressgen, Ann Arbor, MI); 
Rabbit Anti-Tau (A0024; DaykoCytomation, Glostrup, Denmark); Mouse Anti-
GAPDH (AM4300; Ambion, Inc., Austin, TX).  
13. Secondary antibodies: Anti-rabbit IgG HRP-linked antibody (7074; Cell 
Signaling, Danvers, MA); Anti-mouse IgG HRP-linked antibody (7076; Cell 
Signaling, Danvers, MA).   
 
Methods 
 
Biotin-avidin-capture methodology 
 
1. Start by harvesting cells and determining protein concentrations by using the Bio-
Rad Dc Protein Assay kit. 
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2. Adjust protein concentrations to 2mg/ml for each sample. The final volume of 
each sample should be 1ml. 
3. Remove 50μl sample from each tube and transfer into a new pre-labeled 1.5ml 
Eppendorf tube. Add DTT (50mM) and NuPage Sample buffer (4x) to each 
sample, heat samples for 10min at 95ºC, and store at -20ºC. This sample is 
referred to as the whole cell lysate. 
4. Add biotin hydrazide (5mM) into the remainder of each sample and incubate 
samples for 2hr in the dark while rotating on a tube rotator. 
5. Following the termination of the incubation time, add sodium borohydride 
(50mM) to each sample and allow samples to incubate for 30min at room 
temperature. The formation of bubbles indicates the reduction of double bonds 
into single bonds. Do not close Eppendorf tubes during this process.  
6. During the 30min incubation time, prepare Amicon Ultra Centrifugal Filter 
Devices. One filter device per sample is needed. Add 1ml 1xPBS into the filter 
device followed by a 20min centrifugation at 2,472 x g. 
7. Upon termination of the 30min incubation, add the entire sample and 2.5ml cold 
1xPBS into the filter device. Spin samples at 2,472 x g for 20min. Remove the 
flow through upon termination of centrifugation. Add another 2.5ml 1xPBS into 
the filter device and centrifuge the sample at 2,472 x g for 20min. Remove the 
flow through upon termination of centrifugation and repeat washes for a total of 
three times.  
8. During the last spin, start to prepare a bead slurry composed of 250μl Streptavidin 
Sepharose High Performance Beads and 250μl 1xPBS. 
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9. Wash the beads for a total of three times by following the subsequent steps: 
a. Vortex bead slurry. 
b. Centrifuge bead slurry on bench top centrifuge at 2,282 x g for approximately 
one minute. 
c. Carefully discard supernatant. 
d. Add 1ml 1xPBS. 
e. Repeat steps a-d. 
10. Upon termination of the three washes of the beads, add 500μl 1xPBS to prevent 
the drying out of the beads until samples are ready to be added.  
11. After termination of the final centrifugation, the approximate volumes of each 
sample have to be estimated. Prepare a new 1.5ml Eppendorf tube for each 
sample and estimate the approximate amount of the sample that did not flow 
through the filter by pipetting this volume into the designated pre-labeled 1.5ml 
Eppendorf tube, thereby paying attention to the volumes that are transferred. 
12. Adjust all samples to an equal volume by adding the appropriate amount of 
1xPBS to the samples.  Volumes of samples have to be adjusted in order to 
facilitate the balancing of the samples on the tube rotator over night.  Transfer 
100μl of each sample into a new pre-labeled 1.5ml Eppendorf tube, followed by 
the addition of DTT (50mM) and NuPage Sample buffer (4x).  Heat the samples 
for 10min at 95ºC and store at -20ºC.  This sample is referred to as the input. 
13. Centrifuge bead slurry on bench top centrifuge at 2,282 x g for approximately one 
minute and carefully remove the entire supernatant.  
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14. Add the remainder of each sample to the appropriate pre-labeled 1.5ml Eppendorf 
tube containing washed Streptavidin Sepharose High Performance Beads and 
carefully mix the beads with the sample. 
15. Allow samples to incubate at 4ºC over night while rotating on a tube rotator. 
16. The following day, prepare 1% SDS, 1M NaCl and 4M urea. Note that the urea 
has to be freshly prepared before every experiment.  
17. Centrifuge samples on bench top centrifuge at 2,282 x g for approximately one 
minute. 
18. Transfer 100μl of the supernatant into a new pre-labeled 1.5ml Eppendorf tube. 
Add DTT (50mM) and NuPage Sample buffer (4x) to each sample.  Heat samples 
for 10min at 95ºC and store at -20ºC.  This sample is referred to as the flow 
through.  Transfer the remainder of the supernatant into another 1.5ml Eppendorf 
tube and store at -20ºC. 
19. Follow steps a-e listed below for the following washes.  Wash the beads twice 
with 1% SDS.  Then wash beads with 4M urea.  Next, beads should be washed 
1M NaCl and finally with 1xPBS.  (Example uses 1% SDS, which is the solution 
used for the first 2 washes.  Save the supernatant after the first wash only.  All 
other supernatants may be discarded): 
a. Add 1ml of 1% SDS to the beads. 
b. Vortex. 
c. Manually invert tubes approximately 20 times.  
d. Centrifuge samples on bench top centrifuge at 2,282 x g for approximately one 
minute.  
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e. Discard supernatant. 
20. Elute beads in 90μl NuPage Sample buffer (4x) and DTT (50mM).  This sample 
is referred to as the eluate. 
21. Vortex all samples and heat for 10min at 95ºC. Store at -20ºC. 
 
Western blotting 
 
1. Heat input, eluate and flow through samples of each experimental condition for 
10min at 95ºC. 
2. Dedicate one lane of your gel to the protein standard by adding 10µl of the 
Precision Plus Protein Standard All Blue Molecular Weight Marker. 
3. Load 10µl of the samples to the gel. Add samples in the following order: input, 
eluate, flow through.  This allows for a more efficient comparison of bands during 
analysis.  Given that the exact protein concentrations cannot be determined 
following the elution of oxidized proteins from the beads, we run Western blots 
assuming equal protein concentrations in the samples.  These results should not be 
used for quantification purposes, but instead for the determination of the oxidative 
status of a protein only.  Moreover, when using 10μl of each, input, eluate and 
flow through from each sample, a total of 10 gels can be run.  However, stripping 
the membrane and incubating it with another antibody allows for the probing of 
one membrane with several different antibodies against proteins of varying 
molecular weights, thereby increasing the number of proteins that can be 
analyzed.   
4. Follow manufacturer’s directions to run the gel. 
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5. Transfer proteins onto a PVDF membrane by following manufacturer’s directions 
for the used transfer apparatus.  
6. Block non-specific primary antibody binding by placing the membrane into 
methanol for 5min. 
7. Allow membrane to dry for 15-20min before placing the membrane into the 
primary antibody. 
8. Prepare primary antibodies of interest in dilution buffer (5% non-fat dry milk, 
1xTBS-Tween 20).  
9. Incubate the membrane in primary antibody over night at 4ºC while shaking on an 
orbital shaker. 
10. Using multiple changes of 1xTBS-Tween 20, wash membrane for a total of 30min 
before adding the secondary antibody.  
11. Prepare appropriate secondary antibodies in dilution buffer (5% non-fat dry milk, 
1xTBS-Tween 20).  
12. Incubate membrane for 1hr at room temperature while shaking on an orbital 
shaker. 
13. Using multiple changes of 1xTBS-Tween 20, wash the membrane for a total of 
30min before adding the chemiluminescent reagent according to manufacturer’s 
specifications and exposing the membrane to film. 
 
Interpretation of data 
 
1. Proteins that have undergone modifications following exposure to oxidative stress 
are identified as a band in the eluate lane (see FIGURE 3.5, Tau). The absence of 
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bands in the lane designated for the eluate sample indicates the absence of 
oxidative modifications of the protein of interest.  
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Discussion 
 The generation of ROS is part of normal human metabolism.  When present at 
low levels and when pro- and antioxidants are balanced, ROS are indeed beneficial for 
proper cellular function (Droge, 2002, Halliwell et al., 2007, Hancock et al., 2001, 
Lambert et al., 2009, Sykes et al., 2007, Ying et al., 2007).  When produced in excess and 
when antioxidants can no longer scavenge and detoxify ROS, tissue injury occurs via the 
ability of ROS to damage macromolecular structures including proteins, lipids and 
nucleic acids (Farmer et al., 2007, Halliwell, 1992, Halliwell et al., 2007).   
In order to identify protein targets of oxidative stress, we used two well defined in 
vitro model systems, namely mature primary neurons which have been exposed to OGD, 
and HT-22 neural cell lines which have been exposed to extracellular glutamate.  As 
described in Chapter II, exposure of neurons to mild (5’) or moderate (15’) OGD did not 
result in cell death.  Neuronal exposure to lethal (90’) OGD, however, significantly 
increased neuronal death (Stankowski & Zeiger et al., 2010).  Using the OxyBlot 
methodology on our primary neuronal model system, we found that levels of total 
oxidized proteins were increased following mild or moderate OGD and decreased 
following lethal OGD (FIGURE 3.3).  These results suggest that even brief exposures of 
neurons to OGD can cause damage to protein structure and function.  The drastic 
decrease in total protein oxidation following lethal OGD may be a reflection of the 
severity of the insult, suggesting that extensive and unrecoverable neuronal death may 
have occurred at this time point.   
Exposure of neurons to OGD results in the activation of a variety of cellular 
signaling cascades, thereby replicating the molecular events triggered in the human brain 
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following TIA or stroke (Gonzalez-Zulueta et al., 2000, Irving et al., 2002, Jarvis et al., 
2001, Joshi et al., 2001, Liu et al., 2006, McLaughlin et al., 2003, Mehta et al., 2007, 
Onteniente et al., 2003, Zeiger et al., 2009).  To investigate the effects of only one of the 
many events triggered by OGD on protein function, namely oxidative stress, we moved 
into the HT-22 neural cell line, which is an excellent and well characterized model of 
pure oxidative stress (Maher, 2005, van Leyen et al., 2005, Wang et al., 2005).  
Moreover, while the OxyBlot methodology used in our in vitro neuronal model system is 
a rapid technique that allows scientists to obtain a general overview of the degree of 
protein damage in a given model system, it does not allow for the identification of 
specific targets of oxidative stress.   
For the identification of specific protein targets of oxidative stress, we used the 
biotin-avidin-capture methodology on our HT-22 model system.  Using HT-22 and CHIP 
overexpressing cells to confirm that this novel methodology is applicable to our in vitro 
model system, we first investigated the effects of oxidative stress on the oxidation status 
of the microtubule-associated protein and CHIP substrate tau.  The tau protein plays a 
major role in regulating neuronal microtubule assembly and stability, is highly abundant 
and has also been extensively demonstrated to be a target of oxidative stress (Avila et al., 
2004, Dias-Santagata et al., 2007, Egana et al., 2003, Goldbaum et al., 2002, Melov et al., 
2007, Poppek et al., 2006, Vanhelmont et al., 2010, Zhu et al., 2000).  Our results 
demonstrated that tau is indeed oxidized in the HT-22 cells, and its degree of oxidation is 
further increased in CHIP overexpressing cells following exposure to acute oxidative 
injury (FIGURE 3.5).  Moreover, the observed molecular weight shift of tau in the eluate 
suggests that phosphorylated tau species are predominant targets of oxidative stress in our 
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model system (FIGURE 3.5).  Of all post-translational modifications that have been 
described for tau, phosphorylation of the tau protein remains the most extensively studied 
one (Avila et al., 2004).  While studies have demonstrated that tau phosphorylation 
mediates the protein’s cellular distribution under physiological conditions, no correlations 
between the phosphorylation of specific tau residues and oxidative stress have been 
made.  Using the HT-22 cell line and the immunblotting methodology to probe for 
different phospho-tau species, Poppek and colleagues demonstrate that the induction of 
oxidative stress by means of hydrogen peroxide results in a subtle change in the pattern 
of tau phosphorylation (Poppek et al., 2006).  The difference in both the nature and 
duration of our insult and that used by Poppek and co-workers is proposed to be 
sufficient to trigger unique and insult-specific phosphorylation patterns of tau (Poppek et 
al., 2006), further underlining the complexity of tau phosphorylation in the context of 
oxidative stress. 
Taken together, the use of the biotin-avidin-capture methodology will not only 
allow for the identification of specific protein targets of oxidative stress, but it will 
subsequently also allow us to elucidate if any of these oxidized proteins are potential 
CHIP substrates and how oxidative modifications of these proteins influence the 
progression of the pathology underlying ischemic stroke.  Moreover, when moving into 
our neuronal in vitro model system of OGD as well as our CHIP knockout mice, we will 
be able to investigate if the targets of oxidative stress differ when a variety of molecular 
events are elicited by the insult and when different levels of CHIP are present. 
Ultimately, understanding and defining the relationship between specific protein 
modifications and subsequent changes in protein function will allow scientists to not only 
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improve their understanding of pathways involved in stress signaling and the pathology 
underlying a multitude of human diseases, but it will also aid in the development of 
novel, safe and effective therapeutics for several human diseases.   
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CHAPTER IV 
 
C-TERMINUS OF HSC70 INTERACTING PROTEIN IS AN ESSENTIAL 
DETERMINANT OF MITOCHONDRIAL STRESS SIGNALING IN NEURONS 
 
Abstract 
Overexpression of the E3 ubiquitin ligase C-terminus of HSC70 interacting 
protein (CHIP) blocks neural cell dysfunction in models of Parkinson’s, Alzheimer’s and 
other neurodegenerative diseases.  We recently reported that CHIP expression is acutely 
increased in post-mortem tissue samples from individuals who suffered ischemic attacks, 
but we also found that chronically elevated CHIP was associated with increased levels of 
ubiquitinated and oxidized proteins as well as decreased proteasome activity.  In this 
work, we report that CHIP knockout animals have high baseline levels of oxidized 
proteins as well as increased expression of the mitochondrial stress associated kinase 
PINK1 and the autophagic marker LC3.  Following neuronal oxygen glucose deprivation, 
CHIP expression increased and relocalized to mitochondria.  Using immunoblotting and 
the biotin-avidin-capture methodology on tissue samples from CHIP deficient animals, 
we found that expression levels of markers of mitochondrial maintenance and dynamics, 
including VDAC, COX IV and mitofusin, remained unchanged compared to wild type  
and heterozygous littermates and that these proteins were also not oxidatively modified.  
However, when mitochondria isolated from these animals were exposed to calcium 
challenge, they underwent significantly accelerated mitochondrial permeability transition 
activities.  These data suggest that CHIP plays an essential role in mitochondrial 
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homeostasis as well as protein turnover, and that under conditions of protein stress, CHIP 
is a crucial regulator of protein and mitochondrial turnover. 
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Introduction  
Mutations in the PARK2 gene, which encodes the RING domain-containing E3 
ubiquitin ligase Parkin, are associated with an autosomal-recessive form of juvenile-onset 
Parkinson’s disease (Helton et al., 2008, Imai et al., 2002).  E3 ubiquitin ligases function 
as part of the ubiquitin proteasome pathway (UPP) mediating the transfer of ubiquitin to 
damaged client proteins, thereby tagging them for proteasomal degradation (McLaughlin 
et al., 2005).  The specificity of the UPP lies at the level of the E3 ligases (McLaughlin et 
al., 2005), yet there is redundancy in the substrates that E3 ligases can tag (Morishima et 
al., 2008).  Specifically, the U-box domain containing E3 ubiquitin ligase CHIP has come 
to the forefront when its acute overexpression has been shown to compensate for loss of 
Parkin function, thereby promoting the removal of damaged proteins from the cell and 
increasing cellular survival (Imai et al., 2002).  
CHIP has predominately been associated with protection from chronic 
neurodegenerative diseases including Parkinson’s and Alzheimer’s diseases (Adachi et 
al., 2007, Dickey & Patterson et al., 2007, Jana et al., 2005, Sahara et al., 2005, Shimura 
et al., 2004).  These studies support a model whereby the acute overexpression of CHIP 
proves to be beneficial for cellular survival, aiding in the removal of damaged proteins 
from the cell (Arndt et al., 2007, Dickey & Patterson et al., 2007).  We recently showed 
that CHIP levels are increased in human tissue following acute ischemic injury, yet we 
found that chronic CHIP overexpression worsens cellular outcome in an acute 
neurological injury setting.  Specifically, CHIP overexpression was associated with 
decreased baseline proteasome activity as well as increased protein ubiquitination and 
oxidation following acute oxidative injury, suggesting either a failure of the cells’ ability 
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to turnover damaged proteins or an increase in the production of damaged proteins.  In 
contrast, decreasing CHIP expression levels enhanced neuronal survival following acute 
oxidative injury, implying that an exquisite balance of CHIP expression is required to 
improve cellular survival (Stankowski & Zeiger et al., 2010).   
While the association of E3 ubiquitin ligases with the clearance of damaged 
proteins via the ubiquitin proteasome pathway is apparent, a previously unknown role of 
E3 ubiquitin ligases, and Parkin in particular, has recently been identified, namely their 
association with mediating autophagy-dependent clearance of damaged mitochondria, or 
mitophagy (Rakovic et al., 2010).  A multitude of studies suggests that Parkin’s ability to 
influence mitochondrial integrity depends on its interaction with the serine-threonine 
kinase, PTEN-induced putative kinase 1 (PINK1).  Although the precise mechanism by 
which PINK1 and Parkin modulate mitochondrial dynamics remains unknown, mounting 
evidence suggests that both proteins function in a common pathway, with PINK1 acting 
upstream of Parkin (Poole et al., 2008, Ziviani et al., 2010). 
In the current study, we focus on the potential role of CHIP in governing 
mitochondrial integrity and mitophagy, as we found that CHIP deficient animals have 
high levels of total oxidized proteins suggesting that excessive levels of ROS may be 
generated in CHIP deficient animals.  Moreover, the lack of CHIP also resulted in 
increased expression of the mitochondrial stress sensor PINK1 and the autophagic marker 
LC3 as well as accelerated stress-induced mitochondrial permeability transition activities.  
Using the biotin-avidin-capture methodology to determine if CHIP deficiency results in 
oxidation of proteins associated with mitochondrial homeostasis and integrity, we found 
that known markers of these processes were not oxidatively modified.  In our 
  99 
 
pathophysiologically relevant model of neuronal oxygen glucose deprivation, CHIP 
expression is not only elevated, but CHIP is also associated with mitochondria suggesting 
a potential role for CHIP in regulating redox tone, mitochondrial integrity and mitophagy. 
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Materials and Methods 
User-friendly versions of all protocols and procedures in this work can be found on our 
website at 
http://www.mc.vanderbilt.edu/root/vumc.php?site=mclaughlinlab&doc=17838. 
 
Reagents  
 Commercial vendors of our chaperone antibodies as well as reagents and supplies 
used for our immunoblotting, immunofluorescence and cell culture experiments are the 
same as we previously described in Brown et al. (Brown et al., 2010) and Stankowski, 
Zeiger et al. (Stankowski & Zeiger et al., 2010).  Additional primary antibodies used for 
immublotting in this study include p66shc (566807, EMD), VDAC, COX IV and Parkin 
(4866, 4850 and 2132, respectively; Cell Signaling), PINK1 and mitofusin (MFN1) (BC 
100-494 and NB 110-58853, respectively; Novus Biologicals) and cytochrome c 
(556433, BD Pharmingen).  Commercially available kits utilized were the DC Protein 
Assay kit (500-0112, Bio-Rad) and the OxyBlot Protein Oxidation Detection Kit 
(Millipore, S7150).  Reagents and materials required for the biotin-avidin-capture 
methodology were obtained from the same companies as previously described 
(Stankowski & Codreanu et al., 2010).  Unless otherwise stated, all other chemicals were 
purchased from Sigma-Aldrich.  
 
Animals 
The generation of CHIP deficient mice used in this study has previously been 
described (Dai et al., 2003).  All animals were maintained on a mixed background of 
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C57BL/6 and 129SvEv.  The Institutional Animal Care and Use Committee at Vanderbilt 
University approved all animal husbandry and experiments.  Genotyping was performed 
by PCR using DNA obtained from tail clippings with primers for the CHIP allele.  The 
primers were purchased from XXIDT and the sequences of the reverse and forward CHIP 
primers used for genotypic analyses were 5' TGA CAG TCC TCC AGT TCC CTG AG 3' 
and 5' AAT CCA CGA GGC TCC GCC TTT 3', respectively.  
 
Determination of total oxidized proteins using the OxyBlot methodology 
Derivatization of oxidized proteins was performed as previously described 
(Stankowski & Codreanu et al., 2010, Stankowski & Zeiger et al., 2010).  Briefly, 
following addition of 50mM DTT to whole brain lysates, samples were divided into the 
derivatization reaction (DR) containing 2,4-dinitrophenylhydrazine and the negative 
control (NC) solution.  Samples were stored at 4ºC and run within seven days.  Equal 
protein concentrations were separated using 4-12% Criterion Bis-Tris gels and processed 
as described in the Immunoblotting section below.  Antibodies specific for the detection 
of oxidized proteins were provided by the manufacturer.  
 
Immunoblotting 
Immunoblotting was performed as previously described (Brown et al., 2010, 
McLaughlin et al., 2001, Stankowski & Zeiger et al., 2010).  Semi quantitative analyses 
of immunoblot results were generated by performing high resolution scans for 
densitometric quantification using the Scion NIH Image J analysis program as previously 
described (McLaughlin et al., 2003). 
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Biotin-avidin-capture methodology 
 Derivatization of specific protein targets of oxidative stress was performed using 
the biotin-avidin-capture methodology as previously described (Stankowski & Codreanu 
et al., 2010).  Briefly, liver mitochondrial extracts from P41 CHIP animals were prepared 
as described in the mitochondrial preparation section described below.  Equal protein 
concentrations (2mg/ml) were incubated with biotin hydrazide (5mM) while rotating in 
the dark for 2hr at RT, after which samples were incubated with sodium borohydride 
(50mM) for 30min at RT.  Samples were then transferred into Amicon Ultra Centrifuge 
Filter Devices (UFC 801024, Millipore), and washed three times via addition of cold 
1xPBS followed by centrifugation for 30min at 2,472 x g.  Following the last wash, a 
100μl aliquot was removed to prepare the input via addition of DTT (50mM) and NuPage 
Sample buffer (4x; NP0007, Invitrogen).  The remainder of the sample was added onto 
Streptavidin Sepharose High Performance Beads (17-5113-01, GE Healthcare) and 
incubated while rotating overnight at 4ºC.  The next day, samples were centrifuged 
briefly at 2,282 x g.  The supernatant of the first spin was saved and a 100μl aliquot of 
this sample was used to prepare the flow through via addition of DTT (50mM) and 
NuPage Sample buffer (4x).  Samples were eluted from the beads by treating twice with 
each of the following reagents: SDS (1%), urea (4M), NaCl (1M) and 1x PBS.  Beads 
were then eluted in 90μl NuPage Sample buffer and DTT (50mM), heated for 10min at 
95ºC and stored at -20ºC.  Proteins were separated by SDS-PAGE gels as described in the 
immunoblotting section above and probed with antibodies specific for mitofusin, VDAC, 
cytochrome c and COX IV.  
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Primary cell culture  
Cortical cultures were prepared from embryonic day 18 Sprague-Dawley rats as 
previously described (McLaughlin & Nelson & Erecinska et al., 1998, Stankowski & 
Zeiger et al., 2010).  Briefly, cortices were digested in trypsin and dissociated.  Resultant 
cell suspensions were adjusted to 335,000cells/ml.  Cells were plated 2ml/well in 6-well 
tissue culture plates containing five 12mm or one 25mm poly-L-ornithine-coated 
coverslip(s) and maintained at 37oC, 5% CO2 in growth media composed of a volume to 
volume mixture of 84% DMEM (11960, Invitrogen), 8% Ham’s F12-nutrients, 8% fetal 
bovine serum, 24U/ml penicillin, 24μg/ml streptomycin, and 80µM L-glutamine.  Glial 
proliferation was inhibited after two days in culture with 1-2μM cytosine arabinoside, 
after which cultures were maintained in Neurobasal medium (Invitrogen) containing 2% 
B27, 2xN2 and 4% NS21 supplements (Chen et al., 2008) with antibiotics.  All 
experiments were conducted 21-25 days following dissociation.   
 
Oxygen glucose deprivation (OGD) 
OGD experiments were preformed between DIV21-25, at which time neurons 
represent at least 95% of the population as assessed by NeuN and GFAP staining 
(McLaughlin & Nelson & Silver et al., 1998).  OGD was performed as previously 
described (Stankowski & Zeiger et al., 2010) by complete exchange of media with 
deoxygenated, glucose-free Earle’s balanced salt solution (150mM NaCl, 2.8mM KCl, 
1mM CaCl2 and 10mM HEPES; pH 7.3), bubbled with 10% H2/85% N2/5% CO2.  
Cultures were exposed to OGD in an anaerobic chamber (Billups-Rothberg) for 90min at 
37ºC.  Upon OGD termination, cells were washed with MEM/BSA/HEPES (0.01% BSA 
  104 
 
and 25mM HEPES) and maintained in MEM/BSA/HEPES/2xN2 for various recovery 
times at the completion of which protein extracts were prepared for immunblotting as 
previously described (McLaughlin et al., 2003), or cells were fixed for 
immunofluorescence as described below. 
 
MitoTracker labeling and immunofluoresence  
MitoTracker Orange is a highly charged positive stain that accumulates in 
mitochondria based on the mitochondrial membrane potential. A working concentration 
of 790nM MitoTracker Orange was added to MEM/BSA/HEPES/2xN2 45min before 
termination of the recovery time points following OGD.  After termination of the 
recovery period, media was removed, the coverslips were washed with 1xPBS, and fixed 
with 4% formaldehyde.  Cells were then permeabilized with 0.1% Triton X-100, washed 
with 1xPBS, and blocked with 8% BSA diluted in 1xPBS.  After 25min of blocking, 
coverslips were incubated in rabbit anti-CHIP (1:500) or rabbit anti-PINK1 (1:500) 
primary antibodies diluted in 1% BSA overnight at 4°C. Cells were then washed in 
1xPBS for a total of 30min and incubated in goat anti-rabbit Cy2 secondary antibody 
diluted in 1xPBS for 1hr.  Cells were then washed for a total of 30min in 1xPBS and 
incubated in 1.4µM DAPI for 10min.  After 30min of additional washing, coverslips 
were mounted via Prolong Gold, and fluorescence was visualized with a Zeiss Axioplan 
microscope equipped with an Apotome optical sectioning slider. 
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Mitochondrial preparation  
 Mitochondrial homogenates were generated from P41 CHIP WT, Het and KO 
animals as previously described (Zeiger et al., 2009).  Briefly, the liver was removed, 
washed in ice-cold 1xPBS and weighed.  The liver was then homogenized in ice-cold 
isolation media (250mM sucrose, 10mM Tris and 2mM EGTA at pH 7.4) using a 7mL 
glass dounce homogenizer at 10mL/g of tissue.  Homogenates were spun at 500 x g for 
10min at 4°C and the supernatant was removed and placed in a new tube.  Supernatants 
were spun at 9,400 x g for 10min.  The pellet was then washed with 10mL of isolation 
media (without EGTA) and spun again at 9,400 x g for 10min.  The remaining pellets 
were resuspended in 1mL of TNEB lysis buffer with protease inhibitors, subject to 
protein assay and either processed for immunoblotting or resuspended in 1mL of EGTA 
free isolation media, subjected to protein assay and processed for the mitochondrial 
permeability transition assay as described below.    
 
Mitochondrial permeability transition assay 
 The mitochondrial permeability transition assay was performed as previously 
described (Zeiger et al., 2009).  Briefly, isolated mitochondria (1mg) were suspended in 
1mL of assay buffer (40mM HEPES, 195mM mannitol, 25mM sucrose, 5mM succinate 
and 1μM rotenone at pH 7.2).  Following a 2min equilibration period, either 50μM or 
100μM Ca2+ was added and the absorbance was measured at 535nm over a 20min period 
at 37oC.  Lag time before the onset of cell swelling was measured by determining the 
time when the maximal rate of change in absorbance was evident following Ca2+ 
addition.  Lag time was normalized to that of the WT CHIP animals.  Data represent the 
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means from four independent experiments + SEM.  Statistical significance was 
determined by two-tailed t test assuming unequal variances with p < 0.05.   
 
Analysis and statistics 
 Except where otherwise noted data were summarized and are represented as mean 
+ SEM. The statistical significance of differences between means was assessed using 
one-way analysis of variance (ANOVA) at the 95% level (p < 0.05), followed by the 
Tukey multiple comparison tests using GraphPad Prism software.  
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Results 
CHIP deficient animals have increased CNS protein oxidation 
 We have previously demonstrated that CHIP expression levels are increased in 
post-mortem human tissue from patients who suffered an ischemic stroke as well as in 
our neuronal in vitro model of stroke (Stankowski & Zeiger et al., 2010).  In contrast to 
the benefits associated with transiently increased CHIP expression in blocking cell death 
in the context of chronic neurological diseases, we found that chronic overexpression of 
CHIP actually worsens cellular outcome following acute ischemic injury.  Decreasing 
CHIP levels, however, increased neuronal tolerance to acute injury, implying that 
chronically increased CHIP expression levels may have previously unappreciated 
deleterious effects (Stankowski & Zeiger et al., 2010).  To further evaluate the effects of 
CHIP deficiency on cell fate in the context of acute injury, we first investigated oxidative 
protein injury by comparing the levels of total oxidized proteins in CNS samples obtained 
from CHIP wild type (WT), heterozygous (Het) and knockout (KO) animals (FIGURE 
4.1), and observed a robust increase, in total protein oxidation in CHIP knockout animals 
(FIGURE 4.1). 
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CHIP deficiency results in increased markers of stress but no change in oxidation of 
essential mitochondrial proteins    
 
 The increase in total oxidized proteins in unstressed CHIP KO animals suggested 
that an endogenous source of reactive oxygen species (ROS) may increase protein 
damage in the absence of CHIP (Halliwell et al., 2007).  Given that the electron transport 
FIGURE 4.1:  CHIP deficient animals have increased CNS protein oxidation.  Whole 
brain lysates from P35 wild type (WT), heterozygous (Het) or knockout (KO) CHIP 
animals were prepared and oxidative protein damage was assessed using the OxyBlot 
methodology.  CHIP KO animals show high levels of total oxidized proteins as compared to 
their WT and Het littermates.  HSC70 and GAPDH serve as loading controls.  Immunoblots 
represent results from three independent experiments.  DN, Derivatization Reaction; NC, 
Negative Control. 
  109 
 
chain of the mitochondria has been recognized as the major source of cellular ROS (Liu 
et al., 2002), we next wanted to determine if proteins associated with mitochondrial 
function and cellular stress were altered in CHIP deficient animals.  Expression levels of 
VDAC, mitofusin and COX IV, which are proteins associated with mitochondrial 
dynamics, integrity and function, remained unchanged in CHIP KO animals (FIGURE 
4.2A).  In contrast, expression levels of PINK1 and LC3, which are associated with 
autophagy-dependent clearance of damaged mitochondria, or mitophagy, were elevated 
in CHIP KO animals (FIGURE 4.2A).   
To determine if the redox stress in CHIP deficient animals causes specific 
modifications of proteins involved in mitochondrial homeostasis, we used the biotin-
avidin-capture methodology on freshly isolated liver mitochondria from CHIP WT, Het 
and KO animals yet found that none of these proteins were subject to carbonyl adduction 
(FIGURE 4.2B).   
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FIGURE 4.2:  CHIP deficiency results in increased markers of stress but no change
in oxidation of essential mitochondrial proteins.  A) Whole brain lysates from P35 
wild type (WT), heterozygous (Het) or knockout (KO) CHIP animals were prepared. 
Proteins were separated on SDS-PAGE gels and probed with antibodies specific to CHIP, 
LC3, VDAC, mitofusin, PINK1, COX IV and HSC70.  CHIP KO animals show increased 
expression of the autophagic marker LC3 as well as the mitochondrial stress associated 
kinase PINK1.  Data are from a representative experiment (n=3).  B) Liver mitochondrial 
extracts were prepared from P41 WT, Het or KO CHIP animals.  Specific protein targets 
of oxidative stress were detected using biotin-avidin-capture methodology.  Protein 
extracts were separated on SDS-PAGE gels and probed with antibodies specific to 
mitofusin, VDAC, cytochrome c and COX IV.  Proteins of interest were not subject to 
oxidative modification.  Immunoblots represent results from three independent 
experiments.  In, Input; E, Eluate; FT, Flow through.   
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Oxygen glucose deprivation increases perimitochondrial CHIP association  
Given that PINK1 and LC3 were subsequently upregulated in CHIP deficient 
animals, we next sought to determine the mechanisms associated with mitochondrial 
stress in CHIP knockout animals using our neuron enriched in vitro model system in 
which cultures were exposed to oxygen glucose deprivation (OGD) for 90min.  We 
observed that while CHIP and PINK1 expression levels were upregulated 1hr following 
the insult, the redox-sensitive adaptor protein p66shc as well as the autophagic marker 
LC3 were robustly increased immediately following termination of OGD (FIGURE 
4.3A).  We next sought to determine if CHIP associates with mitochondria.  Six hours 
following exposure of mature neurons to OGD, we detected mitochondrial co-
localization of CHIP, indicating that CHIP may directly regulate mitochondrial tone 
(FIGURE 4.3B, arrows).  Moreover, a stabilization of PINK1 at the mitochondria was 
also detected at 6hr following OGD (FIGURE 4.3C, arrows). 
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FIGURE 4.3: Oxygen glucose deprivation increases perimitochondrial association of 
CHIP.  Neuron enriched primary cultures were exposed to oxygen glucose deprivation 
(OGD) for 90min after which expression profiles as well as intracellular localization of 
proteins associated with mitochondria were analyzed at varying time points.  A) Whole cell 
extracts of neuronal cultures were harvested immediately (0hr), 1hr, 3hr, 4hr, 5hr, 6hr or 24hr 
following exposure to OGD.  Proteins were separated on SDS-PAGE gels and probed for 
CHIP, PINK1, p66shc, LC3 and HSC70.  While p66shc and LC3 expressions levels are 
increased immediately following the insult, CHIP and PINK1 expression levels increased
robustly at 1hr. Immunoblots represent results from three independent experiments.  Six 
hours following neuronal exposure to OGD, neurons were loaded with MitoTracker Orange 
and co-stained with B) CHIP or C) PINK1.  Both proteins associate with mitochondria at this 
time point (arrows).  
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CHIP deficiency increases stress-induced mitochondrial transition activities 
 Given the association of CHIP with mitochondria, we next sought to determine if 
CHIP regulated mitochondrial stress signaling.  Using intact mitochondria from liver of 
WT, Het and KO CHIP animals, we found a significant increase in Ca2+- induced 
mitochondrial permeability transition activities in CHIP KO animals as compared to WT 
or Het littermates.  Notably, CHIP Het mice showed more rapid stress induced 
mitochondrial permeability transition activities than WT animals, yet this response was 
not as robust as that observed in the CHIP KO animals (FIGURE 4.4A, B).  Taken 
together, these data suggest that CHIP is an essential regulator of mitochondrial health 
and degradation of injured mitochondria. 
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FIGURE 4.4:  CHIP deficiency increases mitochondrial transition activities induced 
by stress.  A) Purified mitochondria from P35 wildtype (WT), heterozygous (Het) or CHIP 
knockout (KO) mice were incubated in the absence or presence of increasing amounts of 
Ca2+, and mitochondrial permeability transition was assessed by measuring alterations in 
absorbance over time. Data are from a representative experiment (n=4).  B) The average lag 
time to mitochondrial permeability transition was measured by determining the maximal 
rate of change and normalized to the corresponding WT mitochondria.  Data represent the 
normalized lag time ± SEM from four independent experiments.  Statistical significance 
was determined by two-tailed t test with p < 0.05 compared to WT mitochondria incubated 
with 50µM (*) or 100µM (#) Ca2+. 
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Discussion 
The presence of biochemically and energetically intact mitochondria is essential 
for neuronal survival.  Mitochondria govern important cellular functions including energy 
production, apoptosis, calcium homeostasis and oxidative stress response (Erecinska et 
al., 1994, Liu et al., 2009).  It has become increasingly evident that mitochondrial 
dysfunction is associated with the onset of a multitude of human diseases, including 
stroke, Parkinson’s and Alzheimer’s disease (Bolanos et al., 2009).  As the accumulation 
of damaged mitochondria is particularly neurotoxic, neurons have evolved powerful 
means to remove injured organelles from the cell (Michiorri et al., 2010).  The molecular 
mechanisms associated with autophagy-based clearance systems are thought to involve 
mitochondrial fission and fusion events as well as the recruitment of stress sensitive 
kinases and ubiquitin ligases (Brown et al., 2010, Kleman et al., 2010).  The process by 
which damaged mitochondria are removed from cells is commonly referred to as 
mitophagy and it is now widely accepted that this process plays a critical role in 
mitochondrial quality control (Krebiehl et al., 2010). 
In the past 5 years, a plethora of studies has focused on the role of mitochondrial 
dysfunction in Parkinson’s disease.  Mutations in both the serine-threonine kinase PINK1 
and the E3 ubiquitin ligase Parkin have been associated with the onset of autosomal 
recessive forms or Parkinson’s disease (Poole et al., 2008, Ziviani et al., 2010).  PINK1 is 
constitutively expressed and targeted to mitochondria where it is rapidly removed under 
normal conditions.  In contrast, under conditions of stress, such as mitochondrial 
depolarization, PINK1 associates with damaged mitochondria where it has been 
associated with mitophagy (Matsuda et al., 2010).  Our work is the first study 
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documenting an increase in PINK1 expression levels following exposure of primary 
neurons to OGD suggesting that signaling pathways similar to those observed in 
Parkinson’s disease may mediate ischemic cell death.  Moreover, the discovery that the 
E3 ubiquitin ligase Parkin is involved in governing mitophagy revealed a previously 
unknown function of E3 ubiquitin ligases.  The finding that CHIP can compensate for the 
loss of function of Parkin suggests that there is redundancy with regard to the protein 
substrates E3 ligases can interact with (Imai et al., 2002).  We therefore investigated 
CHIP’s possible role in governing mitochondrial homeostasis.  
In this work, we sought to identify the mechanism associated with increased 
protein oxidation observed as a consequence of CHIP deficiency.  CHIP has been shown 
to be neuroprotective when transiently overexpressed in vitro (Adachi et al., 2007, 
Dickey & Kamal et al., 2007, Dickey & Patterson et al., 2007, Dikshit et al., 2007, Jana et 
al., 2005, McDonough et al., 2003), yet chronic CHIP overexpression is associated with 
proteasome dysfunction and increased vulnerability to oxidative stress (Stankowski & 
Zeiger et al., 2010).  In addition to previous studies demonstrating increased levels of 
lipid peroxidation in various tissues from CHIP knockout animals as determined by 
measuring levels of 8-isoprostanes (Min et al., 2008), our data demonstrate a dramatic 
increase in protein carbonyl group formation in these mice.  Moreover, loss of CHIP was 
associated with increased expression of the mitochondrial redox sensor PINK1 and the 
autophagic clearance protein LC3.  Expression levels of proteins involved in 
mitochondrial integrity and function, however, including VDAC, mitofusin and COX IV 
remained unchanged.  To identify specific protein targets of oxidative stress, we used the 
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biotin-avidin-capture methodology and found that these proteins were not directly 
modified by oxidation. 
Due to the increased expression levels of PINK1 and LC3 in CHIP deficient 
animals, we next sought to investigate the relationship between CHIP and the 
mitochondria.  Using our neuronal in vitro model system of OGD, we showed that in the 
presence of a pathophysiologically relevant stressor, expression levels of the redox-
sensitive adaptor protein p66shc are immediately upregulated.  We have previously shown 
that p66shc rapidly translocates to damaged mitochondria in the presence of oxidative 
stress in order to evoke signaling cascades associated with governing autophagy (Brown 
et al., 2010, Kleman et al., 2010).  Interestingly, the expression levels of the autophagic 
marker LC3 also increase rapidly following OGD, suggesting that p66shc-activated 
signaling pathways lead to the recruitment of the autophagic machinery in an attempt to 
remove damaged mitochondria from the cellular environment.   
Similarly, our data also demonstrate that PINK1 expression levels start to increase 
1hr following the initial insult.  Given that studies have shown an increased accumulation 
and stabilization of PINK1 at the mitochondria following stress where it recruits other 
chaperones and proteins to damaged mitochondria (Matsuda et al., 2010), it may be 
suspected that p66shc is involved in PINK1’s recruitment to damaged mitochondria.  
Finally, the expression levels of CHIP are increased following OGD, suggesting that 
PINK1 may, in turn, recruit CHIP to damaged mitochondria.  Using immunofluorescent 
analyses, we demonstrate that not only is PINK1 recruited to mitochondria following 
oxidative stress, but so is CHIP.  These data further suggest a relationship between CHIP 
and the mitochondria.  In order to identify the possible mechanisms regarding CHIP’s 
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involvement in governing mitochondrial function, we moved back into our CHIP 
knockout model system.  Using isolated mitochondria from CHIP deficient mice, we 
demonstrate for the first time that loss of CHIP is associated with accelerated 
mitochondrial permeability transition activities.  The precise mechanism by which CHIP 
governs mitochondrial transition activities has yet to be elucidated.  Yet, we hypothesize 
that CHIP is recruited to damaged mitochondria following stress where it may interact 
with the mitochondrial associated protein VDAC, thereby preventing the opening of this 
channel and the release of pro-apoptotic factors from the mitochondria into the cell.  Due 
to VDAC’s location in the outer mitochondrial membrane, it presents a suitable and 
immediate target for interaction with CHIP.  However, we also speculate that CHIP may 
either interfere at other levels of the mitochondrial permeability complex or aid in 
sequestering activated caspases and other cell-death proteins.  
Taken together, this work reveals a unique mechanism whereby CHIP acts as an 
essential regulator of redox tone and may be involved in governing mitophagy.  
Moreover, in combination with our recent data demonstrating that CHIP overexpression 
is associated with decreased neuronal survival, these data underscore the importance of 
an exquisite balance of CHIP levels required to maintain cellular health under conditions 
of protein stress.   
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CHAPTER V 
 
SUMMARY AND FUTURE DIRECTIONS 
 
 In the last decade, over 100 studies have provided evidence that acute 
overexpression of CHIP has neuroprotective potential in the context of chronic 
neurodegenerative diseases, including Parkinson’s and Alzheimer’s disease (Dickey & 
Kamal et al., 2007, Dickey et al., 2008, Dickey & Patterson et al., 2007, Dikshit et al., 
2007, Hohfeld et al., 2001, Imai et al., 2002, Ko et al., 2009, Petrucelli et al., 2004, 
Sahara et al., 2005, Shimura et al., 2004, Williams et al., 2009).  CHIP functions as a  
HSP70 co-chaperone and an E3 ubiquitin ligase (Qian et al., 2006).  These studies afford 
the protective role of CHIP not only in its ability to influence HSP70’s folding activities 
and expression levels, but also in its ability to ubiquitinate damaged client proteins for 
their subsequent proteasomal degradation (Arndt et al., 2007, Jiang et al., 2001, 
Kampinga et al., 2003, Murata et al., 2003, Murata et al., 2001).  Despite the benefits 
associated with acute CHIP overexpression in models of chronic neurodegenerative 
diseases, CHIP’s role in determining neuronal fate in acute neurological injury, including 
ischemic stroke, has previously not been examined.  
 We found that CHIP expression is increased in post-mortem tissue samples from 
patients who suffered TIAs or ischemic stroke (Stankowski & Zeiger et al., 2010).  We 
initially hypothesized that the increase in CHIP expression levels observed in patients 
who suffered from TIA or stroke was a means of neurons to remove damaged proteins 
from the cellular environment and to enhance neuronal survival.  We observed however, 
  120 
 
that the chronic overexpression of CHIP is detrimental to neuronal survival when neural 
cells were exposed to stroke-like injury (Stankowski & Zeiger et al., 2010).  
Mechanistically, this effect appears to be dependent upon either the excessive oxidation 
of protein substrates or the inability of cells to remove damaged proteins from the cellular 
environment.  These studies suggest that long-term changes in CHIP are likely a poor 
therapeutic target for chronic disease treatment.  
 
Neuronal OGD increases oxidative protein damage and alters proteasome function 
in vitro 
 
 Ischemic stroke triggers a multitude of molecular events, all of which contribute 
to the observed neuronal damage and death.  Using our neuronal in vitro model system of 
oxygen glucose deprivation (OGD), we not only found that CHIP expression levels were 
increased following mild or moderate OGD, but so were the levels of total oxidized 
proteins.  These observations are in keeping with other studies in which we observed that 
neurons can withstand high levels of oxidative stress as long as the energetic status is 
maintained (Brown et al., 2010).  Moreover, these data confirmed that our in vitro model 
system of OGD presents a pliable platform to capture the earliest molecular events 
following acute injury (Stankowski & Zeiger et al., 2010, Zeiger et al., 2010).  In 
contrast, exposure to lethal OGD resulted in a robust decrease in total protein oxidation 
levels, underscoring the swift nature of death following severe stress in which cells 
experience rapid, unrecoverable damage (Stankowski & Zeiger et al., 2010).   
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Effects of neuronal OGD on protein oxidation 
While measurements of total protein oxidation in our OGD model were obtained 
24hr following the insult, the identification of both the specific protein targets of 
oxidative stress and the temporal profile of protein oxidation following ischemic stroke 
are areas of intense interest.  Defining the relationship between specific oxidative protein 
modifications and changes will allow for a better understanding of pathways involved in 
stress signaling and for the potential identification of biomarkers and novel therapeutic 
targets.  These experiments are of high clinical value, as studies aimed at interfering with 
oxidative protein damaged have failed to recapitulate the successful results obtained 
using animal models of ischemic stroke (Chacon et al., 2008, Maples et al., 2004, Shuaib 
et al., 2007).   
The best-known antioxidant study is the Stroke-Acute Ischemic NXY Treatment 
(SAINT) trial in which the effect of the free-radical spin trap disodium 2,4-disulfophenyl-
N-tert-butylnitrone (NXY-059) was assessed on outcome following acute ischemic stroke 
(Chacon et al., 2008, Shuaib et al., 2007).  The first phase of the SAINT trials led to 
positive outcomes as the co-administration of NXY-059 with the thrombolytic t-PA 
within the first 4hr following symptom onset resulted in decreased rates of intracranial 
hemorrhage (Chacon et al., 2008).  However, during Phase II, there was actually no 
statistically significant difference between the frequency of intracranial hemorrhage in 
patients treated with t-PA in combination with NXY-059 or placebo (Shuaib et al., 2007).   
NXY-059 acts as a free-radical spin-trap, scavenging highly reactive and unstable 
radicals (Kubow et al., 1984, Maples et al., 2004).  Despite the benefits that were 
observed in animal models of ischemic stroke and in the first phase of the SAINT clinical 
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trials (Chacon et al., 2008), it has been hypothesized that the enzymatic products of 
NXY-095 may be neurotoxic (Chacon et al., 2008).  Moreover, it remains to be 
determined if total levels of ROS actually decrease via the use of spin-traps and if spin-
traps have a preference for certain free radical species.  This is of particular importance as 
the biochemistry of oxidative pathobiology is highly complex, implying that each 
individual disease may require a specific and optimal antioxidant therapy, which may 
have to be administered early on in chronic neurological disorders or to at-risk patients of 
acute neurological disorders (Delanty et al., 2000, Singh et al., 2004).  These outstanding 
questions underline the fact that more research regarding the mechanisms of  free radical-
scavenging by antioxidants is required in an attempt to develop more targeted and 
ultimately safer antioxidant therapies to narrow the window of oxidative protein damage 
and to improve outcome. 
 
Effects of neuronal OGD on protein turnover 
While identifying specific protein targets of oxidative stress is important, 
investigating the effects of mild, moderate or lethal OGD on the proper function of a 
variety of protein clearance systems, including proteasomal degradation and autophagy, 
are becoming increasingly recognized as alternate means to block neuronal death.  Our 
data demonstrate that mild or moderate OGD does not interfere with proteasome 
function, yet lethal OGD results in a significant decrease in proteasome activity.  While 
the removal of damaged proteins appears to be fully functional following mild or 
moderate OGD, it remains unknown at which time point following lethal OGD 
proteasomes start to fail.   
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Furthermore, the investigation of the composition and localization of proteasomes 
not only within different brain regions but also within different subcellular neuronal 
compartments may provide new insight into regional vulnerability to ischemia and how 
proteasome expression correlates with E3 ligase expression.  Using two-dimensional 
Blue Native/SDS-PAGE and tandem mass spectrometry analyses, studies have recently 
identified the presence of different proteasome populations within eukaryotic cells 
(Shibatani et al., 2006).  Specifically, these studies found that in contrast to the traditional 
notion suggesting that proteasomes always consist of a 20S core and two adjacent 
regulatory subunits, emerging evidence suggests that proteasomes may be composed of 
the 20S subunit only, a singly-capped 20S subunit or a doubly-capped 26S proteasome 
(Brooks et al., 2000, Shibatani et al., 2006, Tai et al., 2010).  Using synaptosomal and 
cytosolic extracts from rat cortices in combination with mass spectrometry, these studies 
have also shown that doubly-capped 26S proteasomes are predominantly located in the 
cortex (Tai et al., 2010).  This evidence suggests that regions which are at high risk for 
stroke may be equipped with unique proteasome families that may also be less efficient in 
removing damaged proteins.  
In addition to a different regional distribution of proteasomes, the subcellular 
localization of proteasomes also changes following neuronal stimulation (Tai et al., 
2010).  Using in vitro model systems of ischemic stroke, protein aggregates were 
observed in close proximity to nuclei and mitochondria (Hu et al., 2001).  One might 
predict that changes in the subcellular localization of proteasomes occur following acute 
ischemic injury as a means of neurons to direct this protein clearance machinery towards 
areas of higher protein damage, such as the nucleus, mitochondrion and ER.  
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While the ubiquitin proteasome pathway was the initial target of this work due to 
its close association with the E3 ubiquitin ligase CHIP, it remains unknown if other 
cellular clearance processes, such as autophagy, can compensate for the loss of 
proteasome function.  Ongoing efforts in the lab have shown that CHIP can translocate to 
the mitochondria following ischemia where it is suggested to be associated with 
autophagy-based removal of mitochondria, or mitophagy.  Knowing if one clearance 
pathway is more resistant to an acute lethal insult would allow us to explore if redirecting 
damaged proteins to a more efficient clearance system could ultimately improve neuronal 
outcome.   
 
Energetic demands for protein refolding and degradation 
The processes underlying protein degradation and refolding are highly dependent 
on the availability of sufficient energy reserves and recent studies have demonstrated that 
the energetic status of a cell plays an essential role in determining protein fate (Arndt et 
al., 2007, Kampinga et al., 2003).  That is, while low levels of ATP direct proteins to the 
refolding machinery, high levels of ATP are associated with increased protein 
degradation (Arndt et al., 2007, Kampinga et al., 2003).  These findings are highly 
intriguing, as in vivo model systems of ischemic stroke have demonstrated that one of the 
most fundamental changes that occurs following ischemia is the precipitous drop of ATP 
within 2 minutes following transient ischemia (Doyle et al., 2008).  These results 
coincide with preliminary data from our lab showing decreased levels of total ATP 
following neuronal exposure to lethal OGD.  This would suggest that in the presence of 
decreased ATP levels, increased protein refolding versus degradation may be detected 
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following ischemic injury (Kampinga et al., 2003).  Yet, in vivo rat focal brain ischemia 
is associated with aggregation of ubiquitinated proteins following the insult (Hu et al., 
2001, Hu et al., 2000), suggesting a disconnect between in vitro models and in vivo 
observations.  Ongoing work in the lab using renilla-luciferase reporter assays in neurons 
exposed to OGD may allow us to determine if a decrease in protein refolding activities 
exists and if folding is associated with improved outcome following acute injury.   
In addition to the energetic status of cells, Arndt and co-workers have 
demonstrated that the association of HSP70 with different co-chaperone networks 
governs protein fate (Arndt et al., 2007).  While we found that CHIP expression is 
increased in neurons following mild or moderate OGD (Stankowski & Zeiger et al., 
2010), it remains to be determined if BAG-1 expression is also altered in this paradigm.  
As described in Chapter I, the association of HSP70 with CHIP and BAG-1 enhances 
HSP70’s degradation activities.  While CHIP is involved in tagging damaged proteins for 
their subsequent proteasomal degradation, BAG-1 has been shown to direct the protein 
complex to the proteasome via its ubiquitin-like domain (Arndt et al., 2007).  It may 
therefore be speculated that in the presence of decreased levels of BAG-1, ubiquitinated 
proteins may not be efficiently transported to the proteasome, thus resulting in their 
intracellular aggregation.  Arndt and colleagues also demonstrated that CHIP can 
associate with HSP70 in the presence of co-chaperones other than BAG-1 (Arndt et al., 
2007).  In contrast to the degradation-promoting activities of BAG-1, HSP70 binding 
protein 1 (HSPBP1) and Bcl-2-associated athanogene 2 (BAG-2) have been found to 
direct the activities of this multi-protein complex toward protein refolding, as HSPBP1 
and BAG-2 can inhibit the ubiquitin ligase activity of CHIP or abrogate CHIP’s 
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interaction with E2 conjugating enzymes, respectively (Arndt et al., 2007).  If co-
chaperones other than BAG-1 associate with HSP70 and CHIP following acute injury, 
one may predict that damaged client proteins are predominantly directed toward protein 
refolding.  Moreover, given the observed accumulation of protein aggregates in models of 
ischemic stroke (Hu et al., 2001, Hu et al., 2000), one may also speculate that refolding 
activities are impaired following acute injury. 
Taken together, these results would ultimately provide further insight into the 
mechanisms underlying protein fate following acute ischemic injury and could allow us 
to identify novel targets for therapeutic intervention.   
 
CHIP overexpression interferes with proteasome function and decreases neural 
survival following acute oxidative injury 
 
 While a multitude of molecular events are elicited in our neuronal in vitro model 
system of OGD, we were particularly interested in elucidating the effects of a pure 
oxidative insult on neural survival in cells that chronically overexpress CHIP, as 
oxidative stress is one of the earliest and most essential events triggered following 
ischemic stroke.  We therefore moved into the HT-22 cell line, as this cell line is not only 
an excellent and well-described model of neural oxidative injury (Maher, 2005, van 
Leyen et al., 2005), but it also allowed us to drive CHIP expression at high levels.  As 
presented in Chapter II, chronic CHIP overexpression resulted in the accumulation of 
polyubiquitinated and oxidized proteins as well as a significant decrease in baseline 
proteasome activity (Stankowski & Zeiger et al., 2010).  Knowing that CHIP 
overexpressing cells are more prone to accumulate damaged proteins in the form of 
protein aggregates, a detailed analysis of the composition of these aggregates using 
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immunoflourescent analyses would provide insight into which proteins associate with 
damaged substrates in an attempt to govern protein fate.  It may be hypothesized that 
molecular chaperones, CHIP, ubiquitin, subunits of the proteasome as well as CHIP 
substrates may be present within these aggregates suggesting the involvement of all of 
these proteins in trying to refold or degrade a given client protein.   
 In addition to an increased formation of ubiquitin aggregates in CHIP 
overexpressing cells, our data in FIGURE 2.7A also show that these inclusion bodies 
predominantly accumulate in close proximity to the nucleus.  This observation is 
particularly intriguing as a recent study by Sha and colleagues demonstrated a role of 
CHIP in the aggresome pathway (Sha et al., 2009).  Aggresome formation occurs around 
the microtubule organizing center in perinuclear location and is now considered to be a 
normal cytosolic response to aggregated proteins.  These so called “holding stations” 
have been shown to form in response to cellular indigestion, a situation in which the rate 
of aggregate formation exceeds the rate of aggregate elimination.  Such an imbalance is 
most likely to occur when cells are confronted with an overload of damaged proteins, 
which overwhelms the proteasome and results in decreased activity of this multicatalytic 
protease (Sha et al., 2009; Kopito et al., 2000).  Given our observation that ubiquitin 
inclusion bodies form in close proximity to the nucleus (FIGURE 2.7A) as well as our 
finding that chronic CHIP overexpression is associated with decreased proteasome 
activity (FIGURE 2.7B), it may be  hypothesized that our observed inclusion bodies are 
indeed aggresomal holding stations (Sha et al., 2009).  To assess if these inclusion bodies 
are aggresomes, additional immunofluorescence studies probing for the mammalian 
histone deacetylase HDAC6, which serves as a linker between the dynein motor and the 
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protein substrate, thereby governing the transport of ubiquitinated protein substrates to 
aggresomal holding stations (Sha et al., 2009), would be required.    
 In the context of proteasome function, the mechanism by which CHIP interferes 
with proteasome activity remains to be elucidated.  It may be assumed that the presence 
of high levels of the E3 ubiquitin ligase CHIP results in excessive protein ubiquitination, 
thereby overwhelming the proteasome, which in turn responds with a decrease in its 
activity.  Moreover, using multiubiquitin-proteasome binding assays, Urushitani and 
colleagues have demonstrated that the S5α subunit of the proteasome is a substrate for 
CHIP (Urushitani et al., 2004).  This finding is of interest as preliminary data from our 
laboratory demonstrated decreased baseline expression levels of the S5α subunit in CHIP 
overexpressing cells.  As a result, it may be speculated that CHIP interferes at the level of 
proper proteasomal assembly.  Similarly, studies have led to the identification of a variety 
of chaperones that are involved in mediating proteasome assembly (Rosenzweig et al., 
2008, Rosenzweig et al., 2008).  Knowing if any of these chaperones present potential 
substrates for CHIP and if the expression levels of these chaperones are decreased in 
CHIP overexpressing cells would further support the notion that CHIP interferes with 
proteasome function at the level of proteasome assembly.   
While these effects of CHIP on proteasome assembly may be considered to be of 
direct nature, a recent study demonstrated that the cellular redox status can also interfere 
with proteasomal function (Silva et al., 2008).  Using purified yeast proteasomes that 
were exposed to hydrogen peroxide and the chelating agent 
diethylenetriaminepentaacetic acid, Silva and colleagues found that cysteine residues of 
the 20S proteasomal core are S-glutathionylated by reduced glutathione (GSH) and that 
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this oxidative modification does indeed decrease the chymotrypsin-like activity of the 
proteasome (Silva et al., 2008).  In preliminary studies, we determined that baseline 
levels of total GSH are elevated in CHIP overexpressing cells, suggesting that the redox 
status in our CHIP overexpressing cells may also contribute to the observed decrease in 
the chymoptrypsin-like activity.  Overall, a follow-up on these results would allow for a 
better understanding of how high levels of CHIP can interfere with proteasome function, 
which in turn would promote the identification of additional targets for therapeutic 
intervention.  
 
CHIP’s role in governing mitophagy 
 While CHIP’s role in the ubiquitin proteasome pathway became apparent after the 
discovery that CHIP acts as an E3 ubiquitin ligase (Jiang et al., 2001, Murata et al., 
2001), a novel role of E3 ligases recently came to the forefront: the involvement of E3 
ligases in governing mitochondrial homeostasis as well as the autophagy-based removal 
of damaged mitochondria, or mitophagy.  Studies in the field of Parkinson’s disease 
demonstrated that the E3 ligase Parkin is recruited to damaged mitochondria where it 
interacts with the serine/threonine kinase PINK1 in an attempt to remove damaged 
mitochondria (Poole et al., 2008, Rakovic et al., 2010, Ziviani et al., 2010).  Studies using 
transgenic fly strains for PINK1 and Parkin demonstrated that these proteins act in the 
same pathway, with PINK1 acting upstream of Parkin (Poole et al., 2008).  It is proposed 
that PINK1 and Parkin govern mitophagy via Parkin’s ability to ubiquitinate the pro-
fusion protein mitofusin, and mutations in either PINK1 or Parkin resulted not only in 
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decreased ubiquitination of mitofusin, but also in increased tissue degeneration due to the 
accumulation of damaged mitochondria (Poole et al., 2008).   
In concert with results obtained from transgenic flies in which Parkin is mutated 
(Poole et al., 2008), studies using Parkin null mice also showed that these animals present 
with mitochondrial abnormalities, including decreased mitochondrial respiratory 
capacity, increased oxidative damage, decreased expression of proteins involved in 
mitochondrial function including subunits of complex I of the ETC, swollen 
mitochondria and fragmented cristae (Abou-Sleiman et al., 2006, Banerjee et al., 2009, 
Malkus et al., 2009, Muqit et al., 2006).  It remains to be discerned, however, if 
mitochondrial morphology and dynamics change in CHIP knockout animals.  While 
Parkin has been shown to mediate the ubiquitination of the pro-fusion protein mitofusin, 
it is unknown if mitofusin is also a substrate for CHIP and if CHIP plays a role in 
mitochondrial dynamics. 
To investigate the relationship between CHIP and mitochondria, we moved into a 
CHIP knockout mouse model system and found increased levels of total oxidized 
proteins in the absence of CHIP.  These data suggest that CHIP deficient animals either 
have problems removing damaged proteins from the cellular environment, or generate 
higher levels of oxidatively damaged proteins.  As mitochondria are the major source of 
endogenous ROS, we sought to further pursue our studies to investigate if CHIP is 
involved in governing mitochondrial homeostasis and potentially mitophagy.  In addition 
to the increased levels of total oxidized proteins, CHIP deficient animals also have 
increased expression levels of the stress sensor PINK1 and the autophagic marker LC3.  
When moving into our neuronal in vitro model system of OGD, we found that CHIP 
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translocates to mitochondria following a lethal insult,  leading us to further pursue the 
potential role of CHIP in mediating mitochondrial health.  We found that CHIP 
deficiency is associated with accelerated stress-induced mitochondrial permeability 
transition activities.  These data support the notion that CHIP is an essential regulator of 
mitochondrial turnover, yet the exact mechanism remains to be elucidated.  We speculate 
that CHIP controls mitochondrial transition activities at the level of the VDAC channel, 
preventing its premature opening and subsequent release of pro-apoptotic factors under 
conditions of stress.  Due to VDAC’s localization in the outer mitochondrial membrane, 
this channel provides the most promising and direct target for CHIP’s interference with 
mitochondrial transition activities.  It is, however, plausible to speculate that CHIP may 
also interfere at other levels of the mitochondrial permeability complex.  For instance, 
studies have demonstrated that HSPs can promote cellular survival by sequestering and 
binding activated caspases and other cell death proteins (Beere, 2005).  It is therefore 
reasonable to hypothesize that CHIP may also interfere with cell death by inhibiting 
mitochondrial release of cytochrome c, preventing the translocation of Bax to 
mitochondria following stress or interfering with the assembly of the apoptosome.  These 
results would provide further insight into the relationship between CHIP and the 
mitochondria and help better understand by which mechanism CHIP interferes with cell 
death.    
 Overall, we are still at the beginning of our understanding regarding how CHIP is 
recruited to the mitochondria.  It remains to be elucidated if changes in mitochondrial 
potential can trigger the translocation of CHIP to the mitochondria, or if CHIP senses the 
presence of fragmented and damaged mitochondria within cells.  It is unknown if CHIP 
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interacts with PINK1 and if this interaction is required for CHIP’s recruitment to 
damaged mitochondria.  While studies have demonstrated that PINK1 does not 
phosphorylate Parkin, and Parkin does not ubiquitinate PINK1 (Vives-Bauza et al., 
2010), it remains to be determined if this same relationship exists between PINK1 and 
CHIP.  Lastly, studies identifying the protein domains of CHIP which govern CHIP’s 
relocalization to damaged mitochondria as well as mitophagy would provide further 
insights into the mechanism underlying CHIP-mediated mitophagy.  Using CHIP mutants 
in an in vitro model system of acute injury would allow us to better understand how 
CHIP mediates mitochondrial dynamics and turnover.  
 
Summary 
 In summary, our results provide novel insight into the complexity underlying 
ischemic stroke.  Not only did we uncover previously unappreciated effects of chronic 
CHIP overexpression on neuronal survival, but we also provided data supporting a novel 
function of CHIP: namely its involvement in mitophagy.  Future studies aimed at 
identifying how CHIP expression levels are regulated and if the use of small molecule 
therapies to exogenously modify CHIP expression in an attempt to increase neuronal 
survival following acute ischemic injury, will allow us to make progress in our quest to 
identify potential targets for therapeutic intervention.  The finding that CHIP is an 
essential regulator of mitochondrial homeostasis presents exciting new avenues that will 
allow us to better understand the complexity of the CHIP protein and how CHIP’s 
involvement in a variety of processes can govern cellular outcome.  
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